使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
My name is Kim and I will be your conference operator today. At this time, I would like to welcome everyone to Valeant's third-quarter 2016 financial results conference call.
我叫 Kim,今天將擔任各位的電話會議接線員。此刻,我謹代表公司歡迎各位參加 Valeant 2016 年第三季財務業績電話會議。
(Operator Instructions)
(接線員指示)
Thank you. Elif McDonald, Director, Investor Relations, you may begin your conference.
謝謝。投資人關係總監 Elif McDonald,您可以開始主持會議。
- Director of IR
- Director of IR
Good morning, everyone. Welcome to Valeant's third-quarter 2016 financial results conference call. Participating on today's call are Joe Papa, Chairman and Chief Executive Officer and Paul Herendeen, Chief Financial Officer. In addition to the slide webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.
各位早安。歡迎參加 Valeant 2016 年第三季財務業績電話會議。今天參與電話會議的有董事長兼執行長 Joe Papa,以及財務長 Paul Herendeen。除投影片網路直播外,今日投影片簡報的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。
Before we begin, we would like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information. In addition, this presentation contains non-GAAP financial measures. For more information about these measures, please refer to slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website.
在開始之前,我們提醒各位,今天的簡報包含前瞻性資訊。請各位花點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。此外,本簡報包含非 GAAP 財務衡量指標。關於這些衡量指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 調節表可於我們網站所張貼簡報的附錄中查閱。
Finally, the financial guidance in this presentation is effective as of today only. It is our policy to update or affirm guidance only through broadly-disseminated public disclosure. With that, it is my pleasure to turn the call over to Joe.
最後,本簡報中的財務指引僅以今日為準。我們的政策是僅透過廣泛發布的公開揭露來更新或確認指引。接下來,我很高興把電話會議交給 Joe。
- Chairman & CEO
- Chairman & CEO
Thank you, Elif. Good morning, everyone. Thank you for joining us on Election Day. We have a lot to cover this morning. We'll do our best to keep this call brief, so everyone gets a chance to vote. This morning, we are going to cover the following topics: first, I'll provide my perspective on our third-quarter performance, where we are seeing improvement and where we need to focus our efforts going forward.
謝謝你,Elif。各位早安。感謝各位在選舉日加入我們。今天早上我們有很多內容要談。我們會盡力讓本次電話會議簡短一些,讓大家都有機會去投票。今天早上我們將涵蓋以下主題:首先,我會分享我對第三季表現的看法、我們看到改善之處,以及未來我們需要聚焦努力的方向。
I will then turn the call over to our new CFO, Paul Herendeen, who will cover our third-quarter 2016 financial results and the results for each of our three new reportable business segments, Bausch + Lomb / International, branded Rx and US diversified products. Paul will then walk through our current expectations with respect to full-year 2016 guidance.
接著我會把電話會議交給我們的新任財務長 Paul Herendeen,他將說明 2016 年第三季財務結果,以及我們三個新的可報導業務部門——Bausch + Lomb/國際、品牌處方藥(branded Rx)與美國多元化產品——各自的表現。Paul 也將說明我們目前對 2016 全年指引的預期。
Next, I will talk about the progress we have made in stabilizing the Company since our last call in August, when we unveiled our plans for the new Valeant and outline the action of plans we have put in place for the year ahead.
接下來,我將談談自 8 月上次電話會議以來,我們在穩定公司方面所取得的進展;當時我們揭示了「新 Valeant」的計畫,並將概述我們為未來一年所制定並已啟動的行動計畫。
Turning now to slide number 4, I'd like to start the call with a few comments about the progress we are continuing to make towards our goal of creating the new Valeant. On the positive side, our third-quarter performance reflects sequential improvements in revenue, operating margin, operating expenses and adjusted EBITDA. Debt reduction is another positive as we have repaid $450 million in debt since the second quarter.
現在請看第 4 頁投影片,我想先就我們持續朝「打造新 Valeant」目標邁進所取得的進展,做幾點說明。正面來看,我們第三季表現反映出營收、營業利益率、營業費用以及調整後 EBITDA 的逐季改善。減債也是另一項正面因素,因為自第二季以來我們已償還 4.5 億美元的債務。
We've also reduced SG&A by $20 million last quarter, while continuing to make research and development investments of over $100 million in the quarter. This was accomplished through a series of operational efficiency projects. Our Durham and GI business are showing signs of growth, which I will talk about in more detail later in the presentation. Finally, we have added two new members to our executive management team, Paul Herendeen and Dr. Louis Yu.
我們也在上季將銷售、一般及行政費用(SG&A)降低了 2,000 萬美元,同時仍在本季持續投入超過 1 億美元的研發投資。這是透過一系列營運效率專案所達成。我們的 Durham 與腸胃(GI)業務已顯現成長跡象,我稍後會在簡報中更詳細說明。最後,我們的高階管理團隊新增了兩位成員:Paul Herendeen 與 Louis Yu 醫師。
That said, we are facing a number of challenges that have adversely impacted our results this quarter and represent headwinds for the business. First, the PDUFA date for brodalumab has been extended by three months, until February 16, 2017. At the same time, we are working through some operating and quality challenges related to manufacturing issues, product recalls and back orders.
話雖如此,我們仍面臨多項挑戰,這些挑戰在本季對我們的業績造成不利影響,並構成業務的逆風。首先,brodalumab 的 PDUFA 日期已延後三個月,至 2017 年 2 月 16 日。同時,我們也正在處理與製造問題、產品召回以及缺貨待補(back orders)相關的一些營運與品質挑戰。
We did receive a warning letter for our Rochester, New York site, secondary to inspections in February 2016 and September 2016. We take this issue very seriously and are working with the FDA to resolve it as soon as possible. To be clear, this does not impact production or sales of our Bausch + Lomb products. We are also facing new generic competition for three of our products: Ofloxin Otic, Ziana and Zegerid.
我們確實收到針對紐約州羅徹斯特(Rochester)廠區的警告信,係因 2016 年 2 月與 2016 年 9 月的稽查所致。我們非常重視此事,並正與 FDA 合作,盡快解決。需要說明的是,這不影響我們 Bausch + Lomb 產品的生產或銷售。我們也正面臨三項產品的新一波學名藥競爭:Ofloxin Otic、Ziana 與 Zegerid。
Finally, we continue to need to address legacy issues, including negative press coverage, litigation and talent retention and severance. In summary, we face some challenges, but we are taking specific actions that will put us on the right track. With that, I'll now turn the call over to Paul to review our third-quarter 2016 financial results.
最後,我們仍需處理歷史遺留問題,包括負面媒體報導、訴訟,以及人才留任與資遣相關事宜。總結而言,我們面臨一些挑戰,但我們正在採取具體行動,使公司回到正確軌道。接下來,我把電話會議交給 Paul,請他回顧我們 2016 年第三季的財務結果。
- CFO
- CFO
Thank you, Joe. Good morning. I'm Paul Herendeen, the relatively new CFO of the Company. I joined the day after Labor Day, so I'm just over two months in. I was formerly the CFO of Zoetis and before that Warner Chilcott.
謝謝你,Joe。各位早安。我是 Paul Herendeen,公司相對新任的財務長。我在勞動節後一天加入公司,所以到現在剛超過兩個月。我先前曾任 Zoetis 的財務長,在那之前則在 Warner Chilcott 任職。
I was attracted to the opportunity to join the team that Joe is building here and to participate in the transformation of Valeant from being a serial acquirer to managing and growing a group of complementary businesses. We face a number of challenges for sure, but I believe that this team, from Joe on down, is the right team to navigate these challenges and build value over time.
我之所以被吸引加入,是因為有機會加入 Joe 在此打造的團隊,並參與 Valeant 的轉型:從一個連續併購者,轉變為管理並成長一組互補業務的公司。我們確實面臨不少挑戰,但我相信這個團隊——從 Joe 到各層級——是能夠駕馭這些挑戰並隨時間建立價值的正確團隊。
As I love to say, value creation is not linear. So we will face setbacks and we will overcome them. We'll work to protect the interest of all the Company's stakeholders, our creditors, our debt-holders, our shareholders and importantly, our 20,000 plus colleagues. We take fire from the press and from folks in the investment community just about everyday, focused on the Company's past. We can't change the things that are in the past, we can only deal with them and change our future.
我常說,價值創造不是線性的。因此我們會遇到挫折,也會克服它們。我們將努力維護公司所有利害關係人的利益:我們的債權人、債券持有人、股東,以及同樣重要的、超過 20,000 名同仁。我們幾乎每天都會受到媒體與投資社群人士的批評,焦點多放在公司的過去。我們無法改變過去的事情,只能面對它們,並改變我們的未來。
We're a new team and we need to earn your trust. We will do that by being a good corporate citizen, by delivering on our commitments and by being transparent in our financial reporting. I think it's worth me spending a moment to provide a basis for how I'll talk about changes in revenue, particularly in our pharma business. When focusing on comparisons with prior-year periods, you need to consider three factors: units, pricing and relative changes in pipeline inventories. Leave one out and you don't have the whole picture.
我們是一個新的團隊,需要贏得各位的信任。我們將透過成為良好的企業公民、履行我們的承諾,以及在財務報導上保持透明來做到這一點。我認為值得花一點時間,說明我將如何談論營收變動,特別是在我們的製藥業務中。在與前一年同期比較時,你需要考量三個因素:銷量(units)、定價(pricing),以及通路庫存(pipeline inventories)的相對變化。少了其中任何一項,你就無法掌握全貌。
In my comments, I will always try to cover these three factors. I'm sure everyone understands volume, the change in our units sold without regard to price. I'll talk about Rx trends as a proxy for trends and end demand for our products. If our unit sales exactly equaled pull-through demand then Rx trends would be highly predictive of our volume trends. But one word of caution, I use Rx data solely as a way of thinking about the trajectory or direction of our unit volume, not as a proxy for actual units sold. I find it very useful as a predictor of the change in unit demand, not the absolute level of unit demand.
在我的評論中,我會一直嘗試涵蓋這三個因素。我相信大家都理解「量」的概念,也就是不考慮價格下我們售出單位數的變化。我會以處方量(Rx)趨勢作為我們產品趨勢與終端需求的替代指標。如果我們的單位銷售量完全等同於終端拉動需求(pull-through demand),那麼 Rx 趨勢將能高度預測我們的銷量趨勢。但要提醒一句:我使用 Rx 數據僅作為思考我們單位銷量軌跡或方向的方法,而不是作為實際售出單位數的替代指標。我認為它對於預測單位需求的變化非常有用,但不是用來判斷單位需求的絕對水準。
Next, when comparing periods, the change in pipeline inventories that occurs in the period needs to be compared with the change in the currently comparative period to determine the relative expansion or contraction. The key word is relative. You could have pipeline contractions in both the prior and current period. If the current period contraction is less than the prior period, you have an expansion, even though pipeline inventories contracted in both periods.
接下來,在比較期間時,需要將該期間發生的通路庫存變動,與目前作為比較基準的期間之變動進行比較,以判斷相對的擴張或收縮。關鍵字是「相對」。你可能在前期與本期都出現通路收縮。如果本期的收縮幅度小於前期,就代表出現擴張,即使兩個期間的通路庫存都在收縮。
Clear as mud, right, but it's important. Finally, in the pharma business, when we talk about price or at least when I do, it's the price that we net after distribution fees, discounts, returns, managed care rebates, government rebates, chargebacks and the impact of co-pay, cards or coupons.
聽起來很難懂,對吧,但這很重要。最後,在製藥業,當我們談到價格——至少我在談時——指的是在扣除通路費用、折扣、退貨、商業保險/管理式醫療回扣、政府回扣、chargebacks,以及自付額(co-pay)、卡片或優惠券影響之後的淨價。
So let's get into the performance in the quarter. Before I get into the segments, let me walk through our results at a high level. On a GAAP basis, we posted revenue of $2.48 billion and a loss of $1.22 billion or $3.49 per fully diluted share. This compares with revenue of $2.79 billion and net income of $50 million or $0.14 per fully diluted share in the prior-year period. Total revenue in the quarter decreased $307 million or 11% compared with Q3 of 2015. I'll talk about the revenue by segment in a minute.
那我們來談本季的表現。在進入各事業部之前,我先從整體層面帶大家看一下我們的結果。按 GAAP 基礎,我們的營收為 24.8 億美元,虧損 12.2 億美元,或每股完全稀釋虧損 3.49 美元。相較之下,去年同期營收為 27.9 億美元,淨利為 5,000 萬美元,或每股完全稀釋盈餘 0.14 美元。本季總營收較 2015 年第三季減少 3.07 億美元,或 11%。我稍後會按事業部說明營收。
The large GAAP loss in the third quarter of 2016 was $1.22 billion as compared to net income of $50 million in the third quarter of 2015. That's primarily due to a good will impairment charge of $1.05 billion that we recorded in Q3. At the conclusion of my remarks regarding the quarter, I will take a minute to talk about how we're thinking about the presentation of our adjusted earnings going forward.
2016 年第三季的 GAAP 大幅虧損為 12.2 億美元,相較於 2015 年第三季淨利 5,000 萬美元。這主要是因為我們在第三季認列了 10.5 億美元的商譽減損費用。在我就本季的評論結束時,我會花一點時間談談我們未來如何思考調整後盈餘的呈現方式。
As we believe that there are some changes we can make that will increase the prominence of our GAAP reporting, while continuing to provide investors with information to facilitate the review of our performance and value. From here forward, I'm going to speak about our results on an adjusted basis.
因為我們認為可以做一些調整,以提高 GAAP 報導的能見度,同時仍持續向投資人提供有助於檢視我們績效與價值的資訊。從這裡開始,我將以調整後基礎來說明我們的結果。
We have provided reconciliations of all adjusted non-GAAP amounts to the applicable GAAP amounts included in our financial statements. First, a quick look at the sequential performance of our business. We believe this is helpful as we continue to execute our stabilization and turn-around plan for the new Valeant.
我們已提供所有調整後非 GAAP 金額與財務報表中相對應 GAAP 金額之調節表。首先,快速看一下我們業務的連續季度表現。我們認為,隨著我們持續執行新 Valeant 的穩定與扭轉計畫,這樣的檢視很有幫助。
Our third-quarter total revenue slightly improved relative to the second quarter. Adjusted COGS was $645 million in Q3 or 26% of revenue. This was steady relative to Q2. Adjusted SG&A expense spend of $642 million, improved sequentially and represented 26% of revenue.
我們第三季的總營收相較第二季略有改善。第三季調整後銷貨成本(COGS)為 6.45 億美元,占營收 26%。相較第二季持平。調整後銷售、一般及管理費用(SG&A)支出為 6.42 億美元,較前一季改善,並占營收 26%。
This improvement was driven by a targeted reduction in selling and A&P expenses, partially offset by higher corporate expenditures of roughly $22 million. That was primarily driven by increased personnel costs resulting from changes in our senior management team as well as professional fees incurred related to our turn-around and also our material weakness remediation efforts.
此改善來自於針對性降低銷售與廣告及促銷(A&P)費用,但部分被約 2,200 萬美元較高的公司層級支出所抵銷。這主要是由於高階管理團隊變動導致的人事成本增加,以及與我們的扭轉計畫相關所產生的專業服務費用,另外也包括我們針對重大內控缺失補救(remediation)工作的相關費用。
This resulted in the improvement to our adjusted operating margin from 42% in Q2 of 2016 to 44% in Q3 of 2016. Our adjusted EBITDA improved to $1.16 billion for Q3. Cash flow from operations improved to $570 million.
因此,我們的調整後營業利益率由 2016 年第二季的 42% 提升至 2016 年第三季的 44%。第三季調整後 EBITDA 提升至 11.6 億美元。營運活動現金流提升至 5.70 億美元。
Flipping to slide 6, I'm now going to go through each of our segments and talk about the changes in revenue and then talk about our operating expenses and R&D in the aggregate. Our new segments highlight the durability and growth potential of our portfolio, which provide the basis for the future of the new Valeant. B+ L / International, our durable growth segment comprised of the global B+ L franchise, global consumer and most of our international markets contributed 47% of our total revenue in Q3 2016.
翻到第 6 張投影片,我現在將逐一說明各事業部,談營收變動,接著再整體說明我們的營業費用與研發(R&D)。我們新的事業部劃分突顯了我們產品組合的韌性與成長潛力,這些構成新 Valeant 未來的基礎。B+L / International,我們的耐久成長事業部,由全球 B+L 特許經營、全球消費者業務以及我們大部分的國際市場所組成,在 2016 年第三季貢獻了我們總營收的 47%。
Our next largest segment, branded Rx contributed 34% to our total revenue in the quarter. Finally, our US diversified products segment, this is our cash-generating segment, includes our neuro and other businesses as well as our generics business, and that contributed 19% of our total revenue this quarter.
我們第二大的事業部——品牌處方藥(branded Rx)——本季貢獻了總營收的 34%。最後,我們的美國多元化產品事業部,這是我們的現金創造事業部,包含神經科與其他業務以及學名藥業務,本季貢獻了總營收的 19%。
A portion of our R&D expense is allocated to the segments, the remainder is managed at the corporate level. Our R&D investment will primarily focus on our B+ L / International and branded Rx franchises from here forward.
我們的研發費用有一部分分攤至各事業部,其餘則由公司層級管理。從現在起,我們的研發投資將主要聚焦於 B+L / International 與品牌處方藥(branded Rx)兩大特許經營。
Turning to slide 7, first let me talk to Bausch and Lomb / International. On a reported basis, B+ L / International segment revenues were up 4% or $43 million compared with Q3 of 2015. Adjusted to exclude the impact of acquisitions, divestitures and discontinuations, what we refer to as same-store sales, B+ L / International revenues declined 1% with a very modest increase in volume partially offset by a modest decrease in net prices. Then we also had a modest negative currency impact of about 1%.
轉到第 7 張投影片,先談 Bausch and Lomb / International。按報告口徑,B+L / International 事業部營收較 2015 年第三季成長 4%,或增加 4,300 萬美元。若調整排除併購、處分與停產的影響(我們稱之為同店銷售),B+L / International 營收下滑 1%,銷量僅小幅增加,部分被淨售價小幅下降所抵銷。此外,匯率也帶來約 1% 的小幅負面影響。
Net of the FX impact, the segment revenue was flat versus Q3 of 2015. On a same-store basis, the positives were the consumer business and Asia. The consumer business was up 6% or $9 million on a 10% volume increase and a 4% price decline. Approximately one-third of the price decline in consumer was attributable to an increased returns provision due to the PeroxiClear recall.
扣除匯率影響後,該事業部營收與 2015 年第三季持平。以同店口徑來看,正面因素來自消費者業務與亞洲。消費者業務成長 6%,或增加 900 萬美元,係由 10% 的銷量成長與 4% 的價格下滑所構成。消費者業務的價格下滑中,約三分之一可歸因於因 PeroxiClear 召回而提高的退貨準備。
Asia was up 6% driven by a 4% increase in volume and a 3% positive currency tailwind, offset by the impact of minus 2% due to price. Europe was down about 3% or $12 million, minus 2% due to FX, volume was down 4% and price was up 3%. The volume decline was driven by a reduction in customer inventory levels in Poland. Without this inventory drawdown, volume would have been approximately flat.
亞洲成長 6%,主要由銷量增加 4% 與 3% 的正向匯率順風帶動,但被價格帶來的 -2% 影響所抵銷。歐洲下滑約 3%,或減少 1,200 萬美元,其中 -2% 來自匯率影響,銷量下滑 4%,價格上升 3%。銷量下滑是由於波蘭客戶庫存水位下降所致。若沒有這次庫存去化,銷量大致會接近持平。
Ophthalmology Rx was down 8% or $9 million, with volume up 2% and price down 10%. Rx's for our Ophthalmic products decreased 9% versus Q3 of 2015. That's due to increased competition and a rebuilding of the sales force due to turnover. Aggregate pipeline inventories increased less than 0.1 months in the quarter, which represented a 0.2-month expansion relative to the change in the prior-year quarter.
眼科處方藥(Ophthalmology Rx)下滑 8%,或減少 900 萬美元,其中銷量上升 2%,價格下滑 10%。我們眼科產品的處方量(Rx's)較 2015 年第三季下降 9%。這是因為競爭加劇,以及因人員流動而重建銷售團隊。本季整體通路庫存增加不到 0.1 個月,相較去年同期的變動,代表相對擴張 0.2 個月。
Sequentially B + L / International revenues declined 3% or $36 million. The driver was revenue declines in Europe, partially due to a reduction in the customer pipeline inventory. Second, is reduced demand in Poland.
以連續季度來看,B + L / International 營收下滑 3%,或減少 3,600 萬美元。主因是歐洲營收下滑,部分是由於客戶通路庫存下降。第二個因素是波蘭需求減弱。
Turning to slide 8, and moving on to the branded Rx segment. Note that the impact of acquisitions, divestitures and discontinuations on branded Rx product revenues for Q3 of 2016 versus 2015 were negligible. Overall, the branded Rx segment was down 23% or about $250 million compared with the year-ago quarter, with a 9% volume decline and a 15% decline in our net selling prices.
轉到第 8 張投影片,接著談品牌處方藥(branded Rx)事業部。請注意,2016 年第三季相較 2015 年,併購、處分與停產對品牌處方藥產品營收的影響可忽略不計。整體而言,品牌處方藥事業部較去年同期下滑 23%,約減少 2.50 億美元,其中銷量下滑 9%,淨售價下滑 15%。
Within the segment, dermatology was down 52% or $224 million on a 30% volume decline and a decline in net prices of 22%. The decline in volume was mainly attributable to Jublia, Solodyn and Ziana. The latter for which generic entered the market this quarter.
在該業務分部中,皮膚科業務下滑52%,或減少2.24億美元,原因是銷量下滑30%以及淨價格下滑22%。銷量下滑主要歸因於Jublia、Solodyn和Ziana。其中Ziana於本季有學名藥進入市場。
In January of this year, we pivoted away from a specially pharmacy model to provide patients with access to our derm products and began to focus on a combination of our unique fulfillment agreements with Walgreen's and improved coverage of our products by managed care. That change has resulted in a rebasing of our dermatology business, a rebasing that continues through Q3.
今年1月,我們從專科藥局模式轉向,改以讓病患能取得我們皮膚科產品為目標,並開始聚焦於我們與Walgreen's的獨特履約協議組合,以及透過受管理醫療(managed care)提升我們產品的給付覆蓋。這項改變使我們的皮膚科業務基期重置,而此重置效應持續至第三季。
The changed model is the primary driver of both the decline in net selling prices due to higher managed care and patient rebates and a 26% decline that we saw in filled Rx's and that's primarily refills compared with Q3 of 2015. Pipeline inventories of our dermatology products increased 0.2 months in the quarter, an expansion of roughly 0.4 months relative to the prior-year quarter.
此一模式變更是兩項變動的主要驅動因素:其一是因受管理醫療與病患回饋(rebates)提高而導致淨銷售價格下滑;其二是與2015年第三季相比,我們已配藥處方(filled Rx)下滑26%,且主要是續配(refills)。本季皮膚科產品的通路庫存(pipeline inventories)增加0.2個月,較去年同期的變動幅度約擴大0.4個月。
I want to point out that the accounting for accruals associated with the Walgreen's agreements and certain gross-to-net items in the dermatology segment can be a bit lumpy on -- that's a technical term, lumpy, on the quarter-to-quarter presentation of revenue. We have had this situation in Q2 and Q3 of 2016. As you look at Q2 net revenue of $188 million and Q3 net revenue of $223 million, please bear in mind that in Q3 we benefited from a true-up of the Walgreen's agreements, a portion of which could be thought of as applying to Q2.
我想指出,與Walgreen's協議相關的應計項目(accruals)以及皮膚科分部某些由毛額到淨額(gross-to-net)項目的會計處理,可能會使季度間的營收呈現有些「不平滑」(這是個技術用語:lumpy)。我們在2016年第二季與第三季都出現過這種情況。當您比較第二季淨營收1.88億美元與第三季淨營收2.23億美元時,請記得第三季受惠於對Walgreen's協議的調整(true-up),其中一部分可視為適用於第二季。
Q3 was depressed by the impact of establishing an opening gross to net accrual for a new coupon program. Normalizing for these two items, you could think of our dermatology net sales as being more like $205 million to $210 million in both Q2 and in Q3. As a new program season, we would expect the quarter-to-quarter variations to moderate.
第三季也受到為新的折價券(coupon)計畫建立期初由毛額到淨額應計(opening gross-to-net accrual)影響而被壓低。若將這兩項因素正常化(normalizing),您可將我們皮膚科淨銷售視為在第二季與第三季皆約為2.05億至2.10億美元。隨著新計畫進入季節性運作,我們預期季度間的波動將趨於緩和。
Turning to GI. GI was down $23 million or 5% with a 5% increase in volume more than offset by a 15% decrease in our net prices across the GI portfolio. The price decline was primarily driven by increased managed care rebates for Xifaxan as we took steps to improve patient access to -- I can't say it -- Xifaxan via better coverage with managed care providers. Rx's for our largest GI product, Xifaxan, increased 14% compared with Q3 of 2015, while aggregate pipeline inventories for our GI products increased 0.2 of a month in the quarter and expanded 0.3 of month relative to the change in the prior-year quarter.
接著看GI(腸胃)業務。GI營收下滑2,300萬美元或5%,其中銷量增加5%,但被GI產品組合整體淨價格下滑15%所抵銷且超過。價格下滑主要是因我們為改善病患取得Xifaxan的可近性而提高了Xifaxan的受管理醫療回饋;也就是透過受管理醫療提供者更好的給付覆蓋來提升—我不太會唸—Xifaxan的可近性。我們最大的GI產品Xifaxan之處方量(Rx)較2015年第三季增加14%,而GI產品的整體通路庫存本季增加0.2個月,且相較去年同期的變動幅度擴大0.3個月。
Sequentially branded Rx revenues were up 16% or $115 million. Part of this increase is attributable to our GI business where our pipeline inventory increased roughly 0.4 of a month relative to Q2. We had a favorable gross to net factor in the quarter. It's important to note that while pipeline inventory in GI increased from Q2 to Q3, it is down year-to-date by one-third of a month, so 0.33 of a month. We viewed normalized net revenues for the GI business in 2016 at about $380 million per quarter.
以季比(sequentially)來看,品牌處方(branded Rx)營收增加16%,或1.15億美元。此增幅的一部分歸因於GI業務,因我們的通路庫存相較第二季約增加0.4個月。本季我們的由毛額到淨額(gross-to-net)因素有利。需要注意的是,雖然GI的通路庫存從第二季到第三季增加,但年初至今(year-to-date)已下降三分之一个月,即0.33個月。我們認為2016年GI業務的正常化淨營收約為每季3.80億美元。
Turning to slide 9, US diversified products. The impact of acquisitions, divestitures and discontinuations on the diversified segment revenue growth for Q3 compared to Q3 of 2015 was negligible. Diversified revenue declined 17% on $92 million on a 10% volume decline and a 7% decrease in our net prices. The big driver was neurology and other, which was down 23% or $96 million with a 13% decrease in volume and minus 10% in price.
接著看第9頁,美國多元化產品(US diversified products)。與2015年第三季相比,併購、出售與停產對第三季多元化分部營收成長的影響可忽略不計。多元化分部營收下滑17%,或減少9,200萬美元,原因是銷量下滑10%以及淨價格下滑7%。主要驅動因素是神經科及其他(neurology and other),下滑23%或減少9,600萬美元,其中銷量下滑13%,價格下滑10%。
The decrease in volume reflects generic competition for Xenazine, Ammonul -- I can't pronounce these and please bear with me, I'm new -- I'm not going to try it and Edecrin. The decrease in net prices reflects the higher group purchasing organization rebates on Nitropress and Isuprel as well as higher managed care rebates. Rx's of our aggregate neurology business were down 25%, while pipeline inventories decreased 0.2 of a month in the quarter, which was flat in the quarter relative to the change in the prior-year quarter.
銷量下滑反映Xenazine、Ammonul—我不太會唸,請見諒,我是新來的—我就不嘗試了—以及Edecrin面臨學名藥競爭。淨價格下滑反映Nitropress與Isuprel的團體採購組織(GPO)回饋提高,以及受管理醫療回饋提高。我們整體神經科業務的處方量(Rx)下滑25%,而通路庫存本季減少0.2個月;相較去年同期的變動幅度,本季為持平。
Moving below the revenue line, I'm going to talk about aggregate results. There's really no slide for this, so we can just stay on the same slide. Gross margin. Gross margin in Q3 2016 declined relative to Q3 of 2015 by 440 basis points, primarily due to product mix as sales of higher margin products such as our dermatology and neurology products declined and sales in Europe, a lower-margin region increased driven in part by the acquisition of Amoun. Foreign exchange also negatively impacted our reported gross margin.
往下看營收線以下,我將談整體結果。這部分其實沒有對應的投影片,所以我們就停留在同一張投影片。毛利率。2016年第三季毛利率較2015年第三季下滑440個基點,主要因產品組合所致:例如我們皮膚科與神經科等高毛利產品銷售下滑;同時,受Amoun併購部分帶動,歐洲(較低毛利地區)的銷售增加。外匯也對我們報告毛利率造成負面影響。
Turning to adjusted operating expenses. Total adjusted SG&A was down 5% or $32 million in Q3 2016 compared with Q3 of 2015. In Q3, 2016 we incurred approximately $22 million of G&A costs primarily driven increased by personnel costs resulting from changes in our senior management team, as well as professional fees incurred related to our turn-around and material weakness remediation efforts. While these expenses are not normal, ongoing types of expenses, they did not qualify to be excluded from adjusted SG&A under our current practices.
接著看調整後營業費用(adjusted operating expenses)。2016年第三季調整後SG&A總額較2015年第三季下滑5%,或減少3,200萬美元。2016年第三季我們發生約2,200萬美元的G&A成本,主要因高階管理團隊變動導致人事成本增加,以及與我們的重整(turn-around)與重大缺失(material weakness)補救工作相關的專業費用。雖然這些費用並非正常、持續性的費用類型,但依我們目前的作法,它們不符合自調整後SG&A中排除的條件。
A&P expenses were down significantly in Q3, 2016 compared to Q3 2015, primarily due to the reduction in DTC advertising for dermatology. Selling expense also decreased slightly, primarily driven by the reduction of our dermatology sales force earlier this year. R&D was roughly flat with the prior-year quarter. We remain committed to investing in R&D to fuel future growth in core segments.
2016年第三季A&P費用較2015年第三季大幅下降,主要因皮膚科的DTC(直接面向消費者)廣告減少。銷售費用也小幅下降,主要因今年稍早我們縮減了皮膚科銷售團隊。R&D與去年同期大致持平。我們仍致力於投資R&D,以推動核心分部未來成長。
The reduced sales and gross margin slightly offset by our lesser operating expenses resulted in our adjusted EBITDA for the quarter, declining 21% or $308 million compared with the prior-year quarter. Below the EBITDA line, net interest expense increased $35 million in Q3 relative to Q3 of 2015, mainly due to the increase in interest rates applicable to our senior secured credit facility -- excuse me, facilities as a result of our April 2016 and August 2016 credit agreement amendments.
銷售與毛利率下降,僅部分被較低的營業費用所抵銷,使得本季調整後EBITDA較去年同期下滑21%,或減少3.08億美元。在EBITDA線以下,第三季淨利息費用較2015年第三季增加3,500萬美元,主要因我們於2016年4月與2016年8月修訂信貸協議後,適用於我們優先擔保信貸融資—抱歉,是融資(facilities)—的利率上升。
Our effective tax rate in Q3 on adjusted pretax earnings increased by 90 basis points due to a true-up during the quarter to a slightly higher expected rate for the full year 2016. The year-to-date rate is 15.5%. We expect this to be our adjusted effective tax rate for the full year. Based on 350.3 million fully diluted shares outstanding, our adjusted net income per share was $1.55 this quarter.
第三季在調整後稅前盈餘基礎上的有效稅率上升90個基點,原因是本季進行調整(true-up),將2016年全年預期稅率略為上修。年初至今稅率為15.5%。我們預期這將是全年調整後有效稅率。以3.503億股完全稀釋在外流通股數計算,本季調整後每股淨利為1.55美元。
Now, turning to slide 10. Now let's discuss our revised guidance. First of all, I think of our guidance as a commitment. I had a pretty good track record with guidance at Warner Chilcott and at Zoetis. That said, Valeant is a Company in transition. This is a turn-around and as with many turn-arounds improvements can sometimes take longer than expected.
現在,轉到第10頁。現在讓我們討論我們修訂後的指引。首先,我把我們的指引視為一項承諾。我在Warner Chilcott以及Zoetis在提供指引方面有相當良好的紀錄。話雖如此,Valeant是一家正處於轉型中的公司。這是一項扭轉局面(turn-around),而且如同許多扭轉局面的情況,改善有時可能比預期花更長時間。
It's a complex Company. I have been here about 60 days. Joe is not here too much longer. I've spent the better part of my first 60 days getting to up speed on our individual business units around the world and pressure testing their forecasts for 2016, for 2017 and beyond.
這是一家複雜的公司。我來這裡大約60天。Joe在這裡也不會待太久了。我在前60天的大部分時間都用來快速熟悉我們在全球各地的各個事業單位,並對其2016年、2017年及更長期的預測進行壓力測試。
What I saw in some instances were units that were running at an unsustainable pace, units that were controlled, but fragile due to constrained resources. We are fixing those things and we are implementing procedures to improve our visibility into the performance of our units and importantly the quality of their results. These changes come at a cost to our near-term revenue and our near-term operating expense run rates. But they are the right thing to do.
我在某些情況下看到的是,有些單位以不可持續的速度運作;有些單位雖然受到控制,但因資源受限而顯得脆弱。我們正在修正這些問題,並正在導入流程,以提升我們對各單位績效的可視性,更重要的是提升其成果的品質。這些改變會對我們短期營收以及短期營運費用的執行率帶來成本。但這是正確的做法。
So as a part of the hit that we're taking in our 2016 guidance reflects those decisions. If you ask me how I feel about the quality of our revised guidance, I'll tell you that I feel good about it, not the level certainly, but the quality of the estimate. But I'll have more confidence when we put out our 2017 guidance and more confidence at the end of Q1 2017 and so on.
因此,我們在2016年指引所承受的部分衝擊反映了這些決策。如果你問我對修訂後指引的品質感受如何,我會告訴你我對它的品質感覺良好——當然不是對其水準,而是對估計的品質。但當我們發布2017年指引時我會更有信心,而在2017年第一季末我會更有信心,依此類推。
I think we've surfaced the vast majority of the previously unknowns and have improved our ability to forecast our results. But there could still be some surprises yet to be discovered. I'm not trying to alarm anyone or walk away from our revised guidance. I'm just letting you know that as time passes, our confidence in our forecasts and our guidance will improve.
我認為我們已揭露了絕大多數先前未知的事項,並提升了我們預測業績的能力。但仍可能有一些尚待發現的意外。我不是要驚動任何人或要背離我們修訂後的指引。我只是想讓各位知道,隨著時間推移,我們對預測與指引的信心將會提升。
Based on our actual year-to-date results and our current estimates for the fourth quarter, we've updated our full-year 2016 guidance for adjusted net income per share to the range of $5.30 to $5.50. We've revised our full-year revenue guidance to the range of $9.55 billion to $9.65 billion and our guidance for adjusted EBITDA for the full year of 2016 to the range of $4.25 billion to $4.35 billion.
基於我們年初至今的實際結果以及對第四季的目前估計,我們將2016年全年調整後每股淨利指引更新至5.30美元至5.50美元的區間。我們將全年營收指引修訂至95.5億美元至96.5億美元的區間,並將2016年全年調整後EBITDA指引修訂至42.5億美元至43.5億美元的區間。
Please note that our current guidance is based on current FX rates. If there were to be a material change to FX rates, it could have an impact on our outlook for the balance of the year. Our guidance does include the recent devaluation of the Egyptian pound.
請注意,我們目前的指引是以現行外匯匯率為基礎。若外匯匯率出現重大變動,可能會影響我們對今年剩餘期間的展望。我們的指引已納入近期埃及鎊的貶值。
Turning to slide 11, we've provided a slide where you can see a bridge to show the elements that cause us to revise our guidance for adjusted net income per share from the prior level. Our revised view of revenue for the full year is the primary driver of the change to our guidance.
轉到第11頁,我們提供了一張投影片,讓你可以看到一個橋接表,顯示使我們將調整後每股淨利指引自先前水準修訂的各項因素。我們對全年營收的修訂觀點是造成指引變動的主要驅動因素。
In Q3, we experienced some unexpected headwinds. First, the back to school season for our dermatology products didn't materialize as we expected, thus dermatology underperformed relative to our expectations.
在第三季,我們遭遇了一些意料之外的逆風。首先,我們皮膚科產品的返校季並未如我們預期般出現,因此皮膚科表現低於我們的預期。
In the European emerging markets, revenue declined in Q3, primarily due to the reduction in customer inventories and softer demand in Poland. We are also impacted by specific events such as the PeroxiClear recall in our consumer business and a supply disruption in our dental business for NeutraSal. From a revenue perspective, as we looked at the balance of the year, our full-year expectations for certain units were reduced in meaningful ways compared with our prior guidance.
在歐洲新興市場,第三季營收下滑,主要是因客戶庫存降低以及波蘭需求轉弱。我們也受到特定事件影響,例如消費者業務的PeroxiClear召回,以及牙科業務中NeutraSal的供應中斷。從營收角度來看,當我們檢視今年剩餘期間時,我們對某些事業單位的全年預期相較於先前指引有顯著下修。
In order, by segment, starting with the largest downward revision, we reduced our expectations for B + L / International, mainly Eastern Europe due to weakness in Poland and the Middle East, particularly Turkey and Egypt. In Egypt, economic challenges and the recent currency devaluation caused us to revise our views. Asia is primarily weaker [than] Australia and Western Europe weakness is driven by Germany.
依事業部門順序,從下修幅度最大者開始,我們下調了B + L/國際(主要是東歐)的預期,原因是波蘭以及中東(特別是土耳其與埃及)疲弱。在埃及,經濟挑戰與近期貨幣貶值使我們修訂了看法。亞洲主要是澳洲較弱,而西歐的疲弱則由德國所驅動。
Within branded Rx, we reduced expectations for dermatology where we underestimated the magnitude and the timing related to the move away from a specially pharmacy model. In dental due to the aforementioned supply issue with NeutraSal. In the diversified segment, we reduced expectations for generics due to competition on Ofloxacin.
在品牌處方藥(branded Rx)方面,我們下調了皮膚科的預期,因為我們低估了從專科藥局模式轉移所帶來的幅度與時點影響。在牙科方面,則是因前述NeutraSal的供應問題。在多元化(diversified)事業部門,我們因Ofloxacin的競爭而下調了學名藥的預期。
Importantly, we did not have to change in any meaningful way our expectations with respect to some of our core growth drivers, including GI, within the branded Rx segment, or US consumer and Ophtha Rx in the B + L / International segment, as those units tracked with our prior expectations. On the cost efficiency side, while we made progress in Q3, we also had incremental costs such as the G&A costs that I discussed earlier related to the turn-around of the business.
重要的是,對於我們部分核心成長驅動因素的預期,我們並未做出任何實質性的調整,包括品牌處方藥部門內的GI,以及B + L/國際部門內的美國消費者與眼科處方藥(Ophtha Rx),因為這些單位的表現符合我們先前的預期。在成本效率方面,雖然我們在第三季取得進展,但也出現了額外成本,例如我先前提到、與業務扭轉相關的一般及行政(G&A)費用。
As we look forward for the remainder of Q4, we believe we have a strong portfolio of businesses on which we can build going forward. However, there's more work to do to improve the revenue growth trajectory in many of these businesses. Our revised guidance does project that Q4 will be down relative to Q3.
展望第四季剩餘期間,我們相信我們擁有一個強健的業務組合,可作為未來發展的基礎。然而,為了改善其中許多業務的營收成長軌跡,仍有更多工作要做。我們修訂後的指引預估第四季將較第三季下滑。
Also included in our revised guidance for the full year 2016, our expenses to activate our strategy to reach primary care physicians in support of Xifaxan for IBSD, also in there our costs to ramp-up our selling effort in women's health in support of Addyi, and costs to prepare for future launches of brodalumab and [Visalta], the timing of which are dependent on FDA actions.
我們修訂後的2016年全年指引亦納入:為啟動我們的策略、以支持Xifaxan用於IBSD而觸及基層照護醫師(primary care physicians)所需的費用;也包含為支持Addyi而在女性健康領域加速擴大銷售投入的成本;以及為未來推出brodalumab與[Visalta]所做的準備成本,其時點取決於FDA的行動。
There's no question that we could dramatically improve our near-term profits by reducing investment, but at great cost to our future. To deliver value to our stakeholders, we need to maximize the value of our existing assets, including by investing behind those brands to be launched. We need to continue to invest in R&D to develop new assets to provide the fuel for longer-term growth.
毫無疑問,我們可以透過減少投資來大幅改善短期獲利,但將以犧牲未來為代價。為了向利害關係人交付價值,我們需要最大化既有資產的價值,包括透過對即將上市的品牌加大投資。我們需要持續投資研發(R&D),開發新資產,為較長期成長提供燃料。
As we move forward, we will continue to review our cost structure, applying a zero-based budgeting model which I will lead as we continue to work to right size the cost structure for our revenue base. However, for now, the reduced revenue expectations for Q4 and the Q3 performance produced too wide a gap to be addressed via near-term revenue -- excuse me, near-term expense reductions. I do want to provide a view of how you might think about 2017 in light of our revised look at 2016.
展望未來,我們將持續檢視成本結構,採用由我主導的零基預算(zero-based budgeting)模式,並持續努力使成本結構與我們的營收基礎相匹配、達到適當規模。然而,就目前而言,第四季營收預期下修以及第三季表現造成的缺口過大,無法透過短期營收——抱歉,是短期費用削減——來彌補。我確實想在我們對2016年修訂看法的背景下,提供你們一個如何看待2017年的觀點。
Off to the midpoint of our now-current 2016 guidance, we expect revenue and adjusted EBITDA to be down compared with 2016. The primary drivers of the decline are both in our diversified products group. First, our neurology and other unit. Second, in the generics unit. In neurology, this decline will be driven by the expected loss of exclusivity of Nitropress in late 2016 or early 2017 and the expected loss of exclusivity of several brands in early 2017, Isuprel, Syprine, Mephyton, virozole, as well as the year-over-year impact of the genericization of Edecrin, which went generic in Q2 of 2016 and the one I can't say, Ammonul, which went generic in March of 2016.
以我們目前2016年指引的中位數為基準,我們預期營收與調整後EBITDA相較於2016年將下滑。下滑的主要驅動因素都在我們的多元化產品事業群。第一,是我們的神經科與其他事業單位。第二,是學名藥事業單位。在神經科方面,這一下滑將由以下因素驅動:Nitropress預期在2016年末或2017年初失去獨家性(loss of exclusivity),以及數個品牌預期在2017年初失去獨家性,包括Isuprel、Syprine、Mephyton、virozole;此外還包括Edecrin學名化的年對年影響(其於2016年第二季轉為學名藥),以及我不能說的那一個Ammonul(其於2016年3月轉為學名藥)。
In generics, the decline reflects increased generic competition for select products. The remainder of our business, the majority of which includes our core assets is expected to be healthy and grow in 2017 top line in the mid single digits and produce operating profit growth in the high single-digits. We simply do not expect to be able to overcome the overall growth drag of the neuro and generics businesses in 2017.
在學名藥方面,下滑反映了部分產品面臨更激烈的學名藥競爭。我們其餘業務(其中大部分包含我們的核心資產)預期表現將維持穩健,並在2017年營收(top line)以中個位數成長,且營業利益以高個位數成長。我們確實不預期能在2017年克服神經科與學名藥業務對整體成長造成的拖累。
Turning to slide 12, the focus on the balance sheet. Our current forecasted liquidity position remains stable. This quarter, our cash flow from operations improved to $570 million relative to $448 million in Q2 2016. We remain committed to using the vast majority of our free cash flow to pay down debt. As of today, we have paid down $1.61 billion of permanent debt, all of this pay-down has been term loans.
接著看第12頁投影片,聚焦資產負債表。我們目前預測的流動性部位仍然穩定。本季,我們的營運活動現金流量改善至5.70億美元,相較於2016年第二季的4.48億美元。我們仍致力於將絕大部分自由現金流用於償還債務。截至今日,我們已償還16.1億美元的長期債務,這些償還全部為定期貸款(term loans)。
We have made all of our scheduled loan amortization payments for 2016. We have also made three of the four scheduled amortization payments for 2017 and will make the remaining 2017 scheduled amortization payment this year, thus leaving us with no mandatory 2017 loan amortization payments by the end of this year.
我們已完成2016年所有排定的貸款攤還付款。我們也已完成2017年四筆排定攤還付款中的三筆,並將於今年完成剩餘的2017年排定攤還付款,因此到今年年底,我們將不再有任何2017年強制性的貸款攤還付款。
Our divesture program is expected to allow us to reduce our quantum of debt further. We continue to expect that between our free cash flow and divesture proceeds we'll be able to reduce debt by more than $5 billion by early 2018.
我們的資產處分計畫預期可讓我們進一步降低債務規模。我們仍預期,透過自由現金流與資產處分所得,我們將能在2018年初之前將債務降低超過50億美元。
Based on the updated guidance, we expect to remain in compliance with the financial maintenance covenants in our credit agreement. As a reminder, we have two financial maintenance covenants: first, a senior secured leverage ratio; second, an interest coverage ratio. At this time, the senior secured leverage ratio has less head room. Even with no asset sales, we expect to remain in compliance, however, asset sales proceeds targeted to repay senior secured debt will increase the cushion in this covenant.
根據更新後的指引,我們預期仍將符合信貸協議中的財務維持性契約(financial maintenance covenants)。提醒一下,我們有兩項財務維持性契約:第一,優先擔保槓桿比率(senior secured leverage ratio);第二,利息保障倍數(interest coverage ratio)。目前,優先擔保槓桿比率的餘裕較小。即使沒有任何資產出售,我們預期仍能符合規定;然而,若將資產出售所得用於償還優先擔保債務,將可增加此契約的緩衝空間。
I'm sure there will be areas that we'll come back to in Q&A, so I'll stop there and turn to how we may modify our presentation of adjusted net income as we go forward. First, we're going to finish out the year based on the same methodology that we've had in place. So that will not confuse things by -- changing that in Q4.
我相信在問答環節我們還會回到一些議題,所以我先到這裡,接著談談未來我們可能如何調整經調整後淨利(adjusted net income)的呈現方式。首先,我們將以既有的方法論把今年剩餘期間做完。因此不會在第四季更改,以免造成混淆。
But we are evaluating changes for next year with a view towards simplifying our presentation so that when viewing our non-GAAP measures, readers will be able to readily find the items that are used to reconcile between GAAP and adjusted numbers in our GAAP financial statements, footnotes and related disclosures. Our goal is to be transparent and enable you to follow along as we measure our performance and estimate our value.
但我們正在評估明年的變更,目標是簡化呈現方式,讓讀者在檢視我們的非GAAP衡量指標時,能夠在GAAP財務報表、附註及相關揭露中,輕易找到用於在GAAP與調整後數字之間進行調節(reconcile)的項目。我們的目標是透明化,並讓各位能跟上我們衡量績效與估算價值的方式。
I'll point out that we're also moving towards the use of adjusted EBITDA as our primary valuation and performance metric. Again, we have not concluded exactly how we will change the presentation of our adjusted earnings yet, but we'll communicate our decisions to you in conjunction with the announcement of our guidance for 2017 and at that time, we will also present our 2016 results on the revised basis so that you'll have that for comparison.
我也要指出,我們正朝向以經調整後EBITDA作為主要估值與績效衡量指標。同樣地,我們尚未確定將如何改變經調整後盈餘的呈現方式,但我們會在公布2017年指引時一併向各位說明我們的決定;屆時也會以修訂後的基礎呈現2016年結果,供各位比較。
I've prattled on for a good long time there, so let me turn it back to Joe.
我剛才講了好一陣子,所以我把時間交還給Joe。
- Chairman & CEO
- Chairman & CEO
Thank you, Paul. I'd now like to talk about the progress made since our second-quarter earnings call. On slide 13, you will see a list of the actions we are taking to stabilize the Company. I'll cover each of these briefly.
謝謝你,Paul。接下來我想談談自我們第二季財報電話會議以來所取得的進展。在第13頁投影片,你會看到我們為穩定公司所採取的一系列行動。我會逐一簡要說明。
Slide 14 begins with the new management additions. We have two talented executives to our senior management team in: Paul Herendeen, as CFO; and Dr. Louis Yu, as Chief Quality Officer. Both Paul and Louis jumped in with both feet on day one and have been making meaningful contributions to the team.
第14頁投影片從新增的管理團隊成員開始。我們的高階管理團隊新增了兩位優秀的主管:Paul Herendeen擔任財務長(CFO);以及Louis Yu博士擔任品質長(Chief Quality Officer)。Paul與Louis在第一天就全力投入,並持續為團隊做出具體貢獻。
Paul joined us shortly after our last earnings call. We are very happy to have him on the team. He has more than 30 years of financial experience and leadership, including 16 years as CFO of Warner Chilcott and MedPointe and two years as the CFO of Zoetis. He's playing a vital role leading our finance functions.
Paul在我們上次財報電話會議後不久加入。我們非常高興他加入團隊。他擁有超過30年的財務經驗與領導資歷,其中包括在Warner Chilcott與MedPointe擔任財務長16年,以及在Zoetis擔任財務長兩年。他在領導我們的財務職能方面扮演關鍵角色。
Dr Louis Yu was Executive Vice President at Global Quality and Compliance at Perrigo for 9.5 years, so I know the great achievements he accomplished at Perrigo. I'm delighted he joined us just last month.
Louis Yu博士曾在Perrigo擔任全球品質與法規遵循(Global Quality and Compliance)執行副總裁長達9.5年,因此我了解他在Perrigo所達成的卓越成就。我很高興他在上個月加入我們。
Moving now to slide 15, before I address the performance of our GI business, I want to acknowledge that we confirmed last week that we are currently in discussions regarding a potential divesture of this business unit. As we said at the time, the discussions may or may not lead to a definitive agreement. We are not going to make any further comments on that process until we have something definitive to say.
接著看第15頁投影片,在我談到我們腸胃(GI)業務的表現之前,我想先說明:我們上週確認,目前正就該事業單位可能的資產處分進行討論。如同我們當時所說,這些討論可能會、也可能不會導致最終協議。在我們有明確結論之前,我們不會就該流程再做進一步評論。
With that in mind, we are pleased to see continuing growth in our GI franchise. Xifaxan monthly prescriptions for Q3 2016 were up 14% compared to Q3 2015. We have seen 24% growth year-to-date versus the first nine months of last year. We are also pleased that other Salix brands have also achieved year-over-year growth. Let me call out two: Uceris, which is up 6%; and Apriso, which is up 5% in terms of prescription growth.
在此前提下,我們很高興看到腸胃(GI)產品線持續成長。2016年第三季Xifaxan的每月處方量較2015年第三季成長14%。今年迄今相較去年前九個月,我們看到24%的成長。我們也很高興其他Salix品牌同樣達成年增。我特別點出兩個:Uceris成長6%;Apriso在處方成長方面成長5%。
I should note that we have identified a primary care solution for the GI business that will be a fourth-quarter event. Finally, we have improved our managed care coverage for oral Relistor tablets which we launched at the beginning of September. We are encouraged that over the last four weeks, TRx for the Relistor family are up 10%.
我也要指出,我們已為腸胃(GI)業務找到一個基層醫療(primary care)解決方案,將在第四季落地。最後,我們已改善口服Relistor錠劑(我們於9月初上市)的健保給付/商業保險(managed care)涵蓋。我們受到鼓舞的是,過去四週Relistor系列的TRx(總處方量)成長10%。
On slide 16, I'd like to talk about our dermatology business. You'll see that the total prescription and new prescriptions are continuing to show recovery.
在第16頁投影片,我想談談我們的皮膚科業務。你會看到總處方量與新處方量持續呈現復甦。
Also Walgreens' third-quarter ASPs, or average selling prices have increased by more than 40% versus the average selling price we achieved in the second quarter. An update on brodalumab, the FDA has notified us that the PDUFA for brodalumab has been extended from November 16, 2016 to February 16, 2017. We plan to work with the FDA over the next three months to resolve questions regarding product labeling and a REMS program.
此外,Walgreens第三季的ASP(平均售價)較我們第二季達成的平均售價提高超過40%。關於brodalumab的最新進展,FDA已通知我們,brodalumab的PDUFA日期已由2016年11月16日延後至2017年2月16日。我們計畫在接下來三個月與FDA合作,解決關於產品標示(labeling)與REMS計畫的問題。
Finally, our near-term product pipeline continues to generate promising developments. We are expecting a Phase 3 data for a novel topical treatment for mild to moderate psoriasis in the second quarter of next year.
最後,我們的短期產品研發管線持續帶來令人振奮的進展。我們預期將在明年第二季取得一項用於輕至中度乾癬之新型外用治療的第三期(Phase 3)數據。
Turning now to slide 17, our consumer healthcare business, which includes popular brands like CeraVe is up 7.7% year-to-date compared to a year-to-date market average of 2%. The team is clearly achieving great performance.
接著看第17頁投影片,我們的消費者健康照護業務(包含CeraVe等熱門品牌)今年迄今成長7.7%,相較之下,市場今年迄今平均成長為2%。團隊顯然正達成非常出色的表現。
Another one of our goals was to stabilize the sales force. On slide 18, you'll see what we have increased our US sales force retention rate to 94% in the third quarter.
我們的另一個目標是穩定銷售團隊。在第18頁投影片中,您會看到我們在第三季將美國銷售團隊留任率提升至94%。
On slide 19, it provides an overview of our continued investment in research and development. The Valeant R&D team is doing great work advancing our new product pipeline. Key upcoming R&D programs include brodalumab for psoriasis, which we're planning to launch in the second quarter of 2017, latanoprostene bunod, an eye drop for interocular pressure with an anticipated launch date of mid-2017. We also have a topical psoriasis product in the pipeline with a NDA filing projected in the first half of 2017. We have a new formulation of rifaxamin, it's plan to enter phase 3 in the second half of 2017.
第19頁投影片概述了我們持續在研發上的投資。Valeant 研發團隊在推進我們的新產品管線方面表現出色。即將到來的關鍵研發計畫包括:用於乾癬的 brodalumab,我們計畫於2017年第二季上市;以及 latanoprostene bunod,一種用於降低眼內壓的滴眼液,預計於2017年年中上市。我們的管線中也有一款外用乾癬產品,預計於2017年上半年提交 NDA 申請。我們還有一種新的 rifaxamin 劑型,計畫於2017年下半年進入第三期臨床試驗。
On the right of the slide, we have presented a summary of our R&D projects. To give a sense of the distribution of these products, we have a total of 134 active projects under way, 76 are in our Bausch + Lomb business, 20 in dermatology and 16 in GI. Importantly, our pipeline is heavily weighted to products that we expect to launch over the next three years. 80% of our project perspective launch in the 2017, 2019 time frame with an additional 20% expected to launch in 2020 and beyond.
在投影片右側,我們呈現了研發專案的摘要。為了讓大家了解這些產品的分布,我們目前共有134個進行中的活躍專案,其中76個在 Bausch + Lomb 業務,20個在皮膚科,16個在腸胃(GI)。重要的是,我們的產品管線高度偏重於我們預期在未來三年內上市的產品。我們的專案中有80%預計在2017年至2019年期間上市,另有20%預計在2020年及之後上市。
Turning now to slide 20, we believe the steps we have taken so far position us to begin the turn-around phase in the coming months. Looking ahead, our priorities will be building the new Valeant team. We've made several key new hires already. We expect to augment the team with additional talent in the coming months.
接著看第20頁投影片,我們相信迄今採取的步驟,使我們在未來幾個月能開始進入扭轉階段。展望未來,我們的優先事項將是打造新的 Valeant 團隊。我們已經完成數項關鍵的新聘任。我們預期在未來幾個月以更多人才來強化團隊。
As Paul mentioned, we are going to continue to build our capability by investing in research and development, quality and new product launch capability. Given the strength of our near-term product pipelines, this will be a key area focus going forward.
如 Paul 所提到的,我們將持續透過投資研發、品質以及新產品上市能力來建立我們的能力。鑑於我們短期產品管線的強勁,這將是未來的重點領域。
Number three is reducing operating costs, we are implementing a zero-based budgeting program that we expect to result in cost savings in the range of $75 million to $100 million in 2017. Before we expect gross profit will increase by an annualized $150 million to $250 million by 2020. We expect to achieve this goal through a disciplined supply chain rationalization. Finally, we are addressing the legacy Valeant issues with strong governance, transparency and sound ethical practices.
第三是降低營運成本。我們正在推行零基預算(zero-based budgeting)計畫,預期在2017年帶來7,500萬至1億美元的成本節省。此外,我們預期到2020年毛利將以年化計算增加1.5億至2.5億美元。我們預期透過嚴謹的供應鏈精簡整合來達成此目標。最後,我們將以強而有力的治理、透明度與健全的道德實務來處理 Valeant 過往遺留的問題。
In summary, on slide 21, I'm pleased the progress we have been made in stabilizing the Company. While it's clear we still have more work to do, I believe we have the right team in place and are on the right path forward. We are focusing on paying down debt, refocusing our portfolio and improving the areas of business that have experienced the highest levels of disruption over the past 12 months.
總結而言,在第21頁投影片,我很高興我們在穩定公司方面已取得進展。雖然很明顯我們仍有更多工作要做,但我相信我們已具備合適的團隊,並走在正確的道路上。我們正專注於償還債務、重新聚焦投資組合,並改善過去12個月受到最大程度干擾的業務領域。
Operator, let's now open up the call for questions.
接線員,現在請開放提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
David Risinger, Morgan Stanley.
David Risinger,摩根士丹利。
- Analyst
- Analyst
Joe and Paul, I was hoping that you could talk us through a little bit more on why the fourth quarter is going to be down so much sequentially versus the third quarter? Normally, the fourth quarter, a drug company actually benefits from seasonality to some degree. In your case, I think that you're guiding to a $200 million decrease in revenue in the fourth quarter relative to the third quarter sequentially. So I just wanted to understand, what's getting worse in the fourth quarter for Valeant?
Joe 和 Paul,我希望你們能更詳細說明一下,為什麼第四季相較第三季會出現如此大的季比下滑?通常第四季藥廠在某種程度上會受惠於季節性因素。但在你們的情況下,我認為你們指引顯示第四季營收相較第三季將季比減少2億美元。所以我想了解的是,Valeant 在第四季到底是哪些方面變得更糟?
Then second, with respect to the Tampa plant, obviously you were aware of issues at the plant early this year. I believe that a 483 was issued in early September, so I'm wondering what worsened at the plant for the 483 to be issued? What to expect and whether you have actual confidence that the facility is going to be fixed soon, such that you can ask for a re-inspection? I'll leave it there. Thank you.
第二,關於坦帕(Tampa)工廠,很明顯你們在今年初就已知道該工廠存在問題。我相信在9月初收到了一份 483,因此我想問的是,工廠發生了什麼惡化,導致 483 被開立?接下來應該期待什麼?以及你們是否真的有信心該設施能很快修復,以便你們可以要求重新稽查?我就問到這裡。謝謝。
- Chairman & CEO
- Chairman & CEO
I'll start on the Q4 versus Q3, but, Paul, you may also want to add some comments. So first comment I'd say is that you are correct, there is a -- Q4 will be less than Q3. We've looked at a couple of things that were part of this discussion in terms of just looking at Q4.
我先回答第四季相較第三季的部分,不過 Paul 你也可以補充一些看法。首先我要說的是,你說得沒錯,第四季會低於第三季。我們針對第四季本身,檢視了幾個納入討論的因素。
First and foremost, I'd say from a leadership point of view, I realize that we put in new leadership in finance and quality. We've changed some of the business unit leaders. As Paul mentioned, we did a very hard review in the QBR, quarterly business review, for each business unit.
首先也是最重要的,從領導層角度來看,我們在財務與品質方面引進了新的領導團隊。我們也更換了部分事業單位的負責人。如 Paul 所提到的,我們在 QBR(季度業務檢討)中,對每個事業單位進行了非常嚴格的審視。
We assess all the things that one needs to assess, whether it be the inventory, the supply capabilities, the number of generic competitors potentially, what's happening with things like -- as Paul talked about, the neuro franchise, the Nitropress and the Isuprel rebates and discounts that we're providing. We looked at some potential disruption in our Business. There's people speculating on potential asset divestments. We're trying to look at a number of things.
我們評估了所有需要評估的事項,不論是庫存、供應能力、潛在的學名藥競爭者數量,或是像 Paul 談到的神經科產品線、Nitropress 與 Isuprel 的回扣與折扣等情況。我們也檢視了業務可能出現的一些干擾。有人在猜測可能會進行資產剝離。我們試圖從多個面向來檢視。
In addition to that, we also looked at the need for long-term investment, I think as Paul mentioned. We said we want to make sure that we are prepared for a primary care effort in the GI business. We want brodalumab, the launch prep to be done well, a relaunch of Addyi, the Visalta launch. A number of things that required some investment, and we wanted to make sure that as we went through those things, we were going to be prepared to go forward into 2017 and beyond.
除此之外,我們也檢視了長期投資的需求,正如 Paul 所提到的。我們表示希望確保我們已為腸胃(GI)業務的基層醫療(primary care)推廣做好準備。我們希望 brodalumab 的上市準備能做得完善,Addyi 的重新上市,以及 Visalta 的上市。有許多事項需要一些投資,而我們希望在推進這些事項的同時,能為2017年及之後的發展做好準備。
But those are really some of the fundamental things at least I would talk about. Paul, I don't know if there's anything else you want to add to my comment.
但以上至少是我會談到的一些根本因素。Paul,我不確定你是否還想對我的說法補充什麼。
- CFO
- CFO
Yes, sure. I'll just kind of walk through from, if you're thinking about in Q3, we posted $1.55. By segment, the things that we expect to change in Q4, or to get to the Q4 number, we're expected the B+ L/International business to be better in Q4 than it was in Q3, so that will contribute to the plus side. The branded Rx we expect to be down predominantly -- well, actually, let me just spit out a couple of factoids so you know what's going on with the B+ L/International group, it's basically international growth off of Q3.
是的,當然。我大致從這個角度帶大家走一遍:如果你回想第三季,我們公布的是1.55美元。按事業部來看,我們預期第四季會變動的部分,或為了達到第四季數字所需的變化,我們預期 B+L/國際業務在第四季會比第三季更好,因此這會帶來正面貢獻。我們預期品牌處方藥(branded Rx)會下滑,主要是——嗯,先讓我提供幾個小重點,讓你了解 B+L/國際團隊的情況:基本上是相較第三季的國際成長。
Second, the branded Rx segment, we're expecting the GI segment to be down from a revenue perspective in the quarter, not because of the fundamental change or performance. That's one of the reasons why I called out the pipeline. We had a pipeline expansion in Q3, which is not going to continue, and, in fact, will likely reverse a little bit in Q4.
第二,品牌處方藥(branded Rx)部門方面,我們預期腸胃(GI)部門在本季營收面會下滑,但不是因為基本面或表現出現變化。這也是我特別提到產品管線的原因之一。我們在第三季有一次通路庫存(pipeline)擴張,這不會延續,而且事實上在第四季很可能會略為反轉。
Durham, we have other adjustments, and expecting that to be slightly down in Q4. We're expecting, also back to the Salix situation for the revenue that it does post, a higher level of GI rebating relative to what we've seen in Q3.
Durham,我們還有其他調整,並預期第四季會略為下降。另外,回到 Salix 的情況,就其入帳的營收而言,我們預期相較於第三季,GI 端的回扣(rebating)水準會更高。
Flipping to the diversified products segment, there's just a number of products in there that are expected to be down in Q4 versus Q3, or drive downward movement, and that's Oflox Otic, it's other generics, it's declines in the neuro and other businesses. Part of that neuro is the continued impact of the discounting that we've done with respect to a couple of products.
轉到多元化產品事業部,裡面有不少產品預期第四季相較第三季會下滑,或帶來向下的變動,包括 Oflox Otic、其他學名藥,以及神經科與其他業務的下滑。其中神經科的一部分,是我們針對幾項產品所做折扣措施持續帶來的影響。
Within OpEx, I called this out a couple of times in my prepared remarks, we are continuing to spend against things that for which there's not currently revenue. So that is a bit of a drag on Q4 as you look at it.
在營業費用(OpEx)方面,我在事先準備的發言中提過幾次,我們仍在持續投入一些目前尚未帶來營收的事項。因此,從第四季的角度來看,這會造成一些拖累。
Those are the big buckets to walk you from the $1.55 down to the amount implied by our guidance. I'll stop there.
以上是把你從 1.55 美元一路帶到我們指引所隱含水準的主要項目。我先說到這裡。
- Chairman & CEO
- Chairman & CEO
Okay. The second part of your question, David, was on our Tampa facility. We stand by the comments that I made previously on the second quarter that, yes, we did receive some comments of 483 on the Tampa facility. We are ready for a re-inspection in that facility within six months of the comment I made in August.
好的。David,你問題的第二部分是關於我們的坦帕(Tampa)廠。我們維持我先前在第二季所做的評論:是的,我們確實收到坦帕廠的 483 意見。我們已準備好在我 8 月所提評論後的六個月內,讓該廠接受複查(re-inspection)。
So we targeted for being ready approximately by the end of the year for a re-inspection early 2017, end of year 2016 for a re-inspection. That would allow us to go forward with our re-inspections that would allow Visalta to get a final approval. So that is still our plan by the end of the year or thereabouts being ready for a re-inspection.
因此我們的目標是大約在年底前準備就緒,以便於 2017 年初進行複查,也就是 2016 年底準備好接受複查。這將使我們得以推進複查流程,並讓 Visalta 取得最終核准。所以這仍是我們的計畫:在年底或前後準備好接受複查。
Operator
Operator
Gregg Gilbert, Deutsche Bank.
Gregg Gilbert,德意志銀行。
- Analyst
- Analyst
Paul, I want to start off -- and welcome, Paul. I wanted to start off asking you about what you said about 2017, to make sure I heard your comments correctly. I think you mentioned revenues would be down year over year, within that your core growth products would be up and overwhelmed by the shrinking diversified, is that right? Can you speak about EBITDA and/or EPS direction in 2017 versus 2016? That's the first question.
Paul,我想先開始——也歡迎你,Paul。我想先就你談到 2017 年的內容提問,確認我是否正確理解你的評論。我想你提到營收將年減;其中核心成長產品會成長,但會被萎縮的多元化業務所抵銷,是這樣嗎?你能談談 2017 年相較 2016 年的 EBITDA 和/或 EPS 走向嗎?這是第一個問題。
Then secondly, on the GI business, a couple pieces within this. Can you discuss what triggered the impairment? Can you give us what the operating expenses are for that business? Lastly, why are Xifaxan inventories at 1.5 months, when most high-volume products in the industry are a couple of weeks? What's the plan with that level? Thanks a lot.
第二,關於 GI 業務,裡面有幾個部分。你能說明是什麼觸發了減損嗎?能否提供該業務的營業費用是多少?最後,為什麼 Xifaxan 的庫存是 1.5 個月,而產業中多數高銷量產品通常只有幾週?對於這個庫存水準的規劃是什麼?非常感謝。
- CFO
- CFO
Sure. I'll start with the question regarding a look at 2017 and sort of summarize what I said. So, basically, you're looking at a 2017 in our diversified group, you've got the neurology and other segment, and you've got generic, so two different pieces. Let's start with neurology.
當然。我先從你關於 2017 年展望的問題開始,並概括我剛才所說的內容。基本上,2017 年在我們的多元化事業群中,你有神經科與其他事業部,還有學名藥,兩個不同部分。先從神經科開始。
Now, we have the expected loss of exclusivity in Nitropress later this year. In early 2017, you've got Isuprel, Syprine, Mephyton and Virazole. Then you've got the year-over-year impact of the previous genericization of Edecrin, which went generic in Q2, and the one I can't pronounce, Ammonul -- someone will help me eventually -- which went generic in March of 2016.
我們預期 Nitropress 會在今年稍晚失去獨家性(loss of exclusivity)。在 2017 年初,還有 Isuprel、Syprine、Mephyton 和 Virazole。此外,還有先前 Edecrin 學名藥化(genericization)的年對年影響——它在第二季轉為學名藥——以及那個我念不出來的 Ammonul——總有一天會有人幫我——它在 2016 年 3 月轉為學名藥。
So you take all of those together, there's a table in the back that's included as part of our deck where we show five quarters' worth of net revenues for products, and at least Nitropress, Isuprel, I think Syprine and Mephyton are included within our top 10 products from that segment. You can look at what that looks like and think about what that means in a situation where we lose exclusivity.
把這些合在一起,我們簡報後面有一張表,列出五個季度各產品的淨營收;至少 Nitropress、Isuprel,以及我想 Syprine 和 Mephyton,都包含在該事業部前十大產品之中。你可以看看那會是什麼樣子,並思考在我們失去獨家性時意味著什麼。
In generics, we've had some good fortune in the generics business this year, which we don't expect to continue on into 2017. So net-net, these are going to be down and they're going to be down in a material way. So my point is, you look at that and say, all right, it kind of -- this is what happens when you have loss of exclusivity for a number of products. You have good fortune, and the good fortune eventually evaporates due to competition.
在學名藥方面,我們今年在學名藥業務上有一些好運氣,但我們不預期這種情況會延續到 2017 年。因此整體而言,這些將會下滑,而且會是相當幅度的下滑。所以我的重點是,你看著這些就會說,好吧——當多項產品失去獨家性時,事情大概就是這樣發生的。你會有好運氣,而好運氣最終會因競爭而消散。
What we have is the remaining business. As I said, the majority of which is comprised of our core assets, which we expect to grow mid-single digits at the top line and high-single digits at the operating profit line or EBITDA line. You can think of it as at the EBITDA line.
我們所擁有的是其餘的業務。如我所說,其中大部分由我們的核心資產構成;我們預期在營收端(top line)以中個位數成長,在營業利益端或 EBITDA 端以高個位數成長。你可以把它理解為在 EBITDA 端的表現。
So that's how we're just providing hand signals, but my last point on this was, we will dig our way out of part of the growth hole created by the LOEs and the changed expectations -- well, changed -- the expectations for the generics business in 2017 v 2016. But we will not crawl all the way out of that hole, so it will be a down year.
所以我們只是提供一些方向性的訊號;但我最後一點是,我們會逐步彌補一部分由失去獨家性(LOEs)以及——嗯,改變的預期——也就是 2017 年相較 2016 年對學名藥業務的預期所造成的成長缺口。但我們不會完全爬出那個坑,所以將會是下滑的一年。
I'm sorry, he had a second question. Hold on.
抱歉,他還有第二個問題。等一下。
- Chairman & CEO
- Chairman & CEO
Gregg also asked about the Xifaxan inventory. As Paul said, some are approximately 1.5 months. I think that is just normal variation that we saw in the quarter. But we wanted to make sure, as Paul said, we'd be very transparent on that number. As the product has grown, it's going to be up, it's going to be down, that's just some normal variations based on what wholesalers purchase for their inventory.
Gregg 也問到 Xifaxan 的庫存。如 Paul 所說,有些大約是 1.5 個月。我認為那只是我們在本季看到的正常波動。但我們想確保,如 Paul 所說,我們會對這個數字非常透明。隨著產品成長,它會上上下下,這只是基於批發商為其庫存所做採購而產生的一些正常波動。
I think -- did we answer the question -- was there a question Gregg had on the GI business on impairments?
我想——我們是否回答了這個問題——Gregg 是否有問到 GI 業務的減損問題?
- CFO
- CFO
On the impairment side, in conjunction with our shifting to our new segment reporting, that triggered an overall review of our intangibles, particularly our goodwill. Through the re-forecasting of various business units, we ended up taking that -- I get the number wrong -- $1.04 billion or so of writedown in goodwill in the quarter. But that was triggered by the change in segment reporting, which causes a fresh look at all of our forecasts for all of our business units, and resulted in the writedown of that particular goodwill.
在減損方面,配合我們改採新的分部報導方式,這觸發了對我們無形資產、特別是商譽的整體檢視。透過對各事業單位重新預測,我們最終在本季認列了——我可能記錯數字——約 10.4 億美元的商譽減記。但這是由分部報導變更所觸發,因而需要重新檢視我們對所有事業單位的各項預測,並導致該筆商譽的減記。
- Analyst
- Analyst
Okay. Thank you.
好的。謝謝。
Operator
Operator
David Maris, Wells Fargo.
David Maris,富國銀行。
- Analyst
- Analyst
A few questions: First, Joe, have you given any thought about the insider trading case that takes place next year? What impact it might have on Valeant, not just the financial penalties, but what might happen if your co-defendant is found guilty as well? If so, can you give us any of your thoughts on that?
幾個問題:第一,Joe,你是否有考慮過明年將進行的內線交易案件?它可能對 Valeant 造成什麼影響——不只是財務罰款,還包括如果你的共同被告也被判有罪,可能會發生什麼?如果有的話,你能分享一些你的想法嗎?
Secondly, it came out last week that there may be criminal charges brought against the Company and two of your executives, one a current consultant, one a former executive. I know you won't comment on that or what the charges might be, but can you tell us, you signed consulting agreements with both of them. Can you tell us what value you're getting from them, because we're not seeing much in the results from that. So what do they do on a day-to-day basis or a weekly basis to earn what you're paying them?
其次,上週傳出公司以及你們兩位高階主管可能會面臨刑事指控,其中一位是現任顧問,另一位是前任高階主管。我知道你不會就此或可能的指控內容發表評論,但你能否告訴我們,你與他們兩位都簽了顧問合約。你能否告訴我們你從他們身上獲得了什麼價值,因為我們從結果上看不太出來。所以他們每天或每週具體做些什麼,來賺取你們支付給他們的費用?
Then lastly, Paul, I know you're new, but do you think, based on what you've seen so far, that you have -- the Company has sufficient liquidity to meet obligations through 2020 or through 2022 without selling assets and without restructuring the debt? Thank you.
最後,Paul,我知道你剛加入,但就你目前所見,你認為——公司在不出售資產、也不進行債務重整的情況下,是否有足夠的流動性來履行義務直到2020年或2022年?謝謝。
- Chairman & CEO
- Chairman & CEO
Okay. A couple comments: Number one, on the insider trading case that you referred to, I really -- David, as you know, I can't really comment on any existing litigation that's ongoing. I will say that I'm delighted that I brought on a brand new General Counsel to join us, Christina Ackermann. She's doing a fabulous job of helping us work our way through all the different cases. But I really can't make any specific comments on any individual case, of course, that's in litigation at this time.
好的。幾點回應:第一,關於你提到的內線交易案件,我真的——David,如你所知,我無法就任何正在進行中的訴訟發表評論。我可以說,我很高興我們延攬了一位全新的總法律顧問加入我們——Christina Ackermann。她在協助我們處理各種不同案件方面做得非常出色。但我當然無法就目前處於訴訟中的任何個別案件作出具體評論。
On the question of the consulting agreements that we have, I do -- I didn't -- I signed the one for Mike. Mike did help us with some consulting as we went through the early stages of my arrival in the Business. Specifically Mike was involved with some of the discussions that we had with the Walgreen's program and putting it originally in place. He gave me some background and some information on that. But since that time, Mike has not been as active, and very limited activity.
至於我們的顧問合約問題,我——我沒有——Mike那份是我簽的。在我剛到這個業務的早期階段,Mike確實在一些顧問工作上協助了我們。具體而言,Mike參與了我們與Walgreen's專案的一些討論,並協助最初的建置。他也提供了我一些背景與相關資訊。但自那之後,Mike就沒有那麼積極,活動非常有限。
We will pay him a consulting arrangement, as he is involved with the Business, and that's exactly what we have agreed to. But I view that as being less and less of involvement, certainly over the last several months that Mike has had less and less involvement with the Company. In fact, almost no involvement with any of the decisions of the Company.
我們會依顧問安排支付他費用,因為他仍與業務有所關聯,而這正是我們所同意的內容。但我認為他的參與度愈來愈低,尤其在過去幾個月,Mike對公司的參與愈來愈少。事實上,幾乎沒有參與公司的任何決策。
On the question, Paul, he asked (multiple speakers) --?
至於那個問題,Paul,他問的是(多位發言者)——?
- CFO
- CFO
Yes, I got it. With respect to liquidity, I think the question was, do we -- without asset sales, do we see a pathway where we maintain adequate liquidity to service the debt? The answer is yes. I do see that pathway. I won't kid anybody, we have a challenge here. It's easy to see.
是的,我明白。就流動性而言,我想問題是:在不出售資產的情況下,我們是否看得到一條路徑,能維持足夠的流動性來償付債務?答案是肯定的。我確實看得到那條路徑。我不會欺騙任何人,我們確實面臨挑戰。這很容易看得出來。
You can see the various towers that we have that we will need to refinance. In order to refinance in a good way, we will need to continue to show progress here from 2017 to 2018 to 2019 and beyond. But the answer -- the short answer, David, is, yes, I am confident that there is the pathway for us to maintain adequate liquidity to service our debt and to refinance it.
你可以看到我們有各種不同的到期債務需要再融資。要以良好的方式完成再融資,我們需要持續展現從2017到2018、2019以及之後的進展。但答案——簡短的答案,David,是:是的,我有信心我們有一條路徑能維持足夠的流動性來償付債務並為其再融資。
Operator
Operator
Louise Chen, Guggenheim.
Guggenheim的Louise Chen。
- Analyst
- Analyst
I've got a few here. So, first question I have was, there's obviously been a lot of headlines around product divestitures naming specific business units and products. I'm just curious, what additional color, aside from what you said on the call, you could give around that?
我這裡有幾個問題。首先,顯然近期有很多關於產品剝離的新聞標題,點名了特定事業單位與產品。我想了解的是,除了你們在電話會議上提到的內容之外,你們還能提供哪些額外的說明?
Then secondly, on Rochester, are there any pending applications out of that facility that are sizeable product opportunities? Then how big is that facility in terms of sales? I know you mentioned the sales will not be affected, but just curious. Then, are there any similarities between that facility and other ones where there could be potential issues amongst other facilities within Valeant? Thank you.
第二,關於Rochester,那個廠是否有任何尚在審查中的申請,屬於規模可觀的產品機會?另外,就銷售額而言,那個廠的規模有多大?我知道你提到銷售不會受到影響,但我只是想了解一下。再者,那個廠與其他廠之間是否有任何相似之處,可能意味著Valeant其他廠也存在潛在問題?謝謝。
- CFO
- CFO
If I might, Joe, do you mind? I'll start, I think, because when you talk about the talk about potential divestitures of assets, I'd say that when people talk about capital allocation, they usually think about investing inside the Company. They think about operating expense, R&D, growth CapEx, investing outside the Company, acquisition of assets, companies, transacting with shareholders.
如果可以的話,Joe,你介意嗎?我先開始回答。我想,當你談到潛在的資產剝離時,我會說,人們談資本配置時,通常想到的是在公司內部投資。他們會想到營運費用、研發、成長型資本支出(CapEx)、在公司外部投資、收購資產或公司,以及與股東進行交易。
What people don't often think about is the disposition of owned assets. I'd say, part of our job is to know the value of assets we own. If we believe that an asset may be worth more in someone else's hands and they'll pay us more than what it may be worth in our hands, we should sell that asset.
但人們不常想到的是處分已擁有的資產。我會說,我們工作的一部分,是了解我們所擁有資產的價值。如果我們相信某項資產在別人手上可能更有價值,而且對方願意支付的價格高於它在我們手上的價值,那我們就應該出售該資產。
Here comes a bombastic statement, as I often like to do that. When someone labels an asset as strategic, it means they want to buy it and can't justify the price or they want to keep it even though someone offers them more than it's worth in their hands. In a nutshell, if someone offers us a value that exceeds, even by a little, the value of the asset in our hands, we should sell that asset. It's simple.
我來一句比較誇張的說法,我常喜歡這麼做。當有人把某項資產貼上「策略性」標籤時,通常意味著他們想買但無法合理化那個價格,或是他們想留著,即使有人出價高於它在他們手上的價值。簡而言之,如果有人給我們的估值超過——哪怕只多一點——該資產在我們手上的價值,我們就應該賣掉那項資產。就這麼簡單。
Now, let me be clear. Our preference is to keep the businesses we identify as core, but not at all costs. This is a requirement for us as a Management team and as governed by our Board that we be responsible in thinking about the value of what we own and whether we can achieve more value by selling it or by continuing to run it. I'll stop.
現在,讓我說清楚。我們的偏好是保留我們認定為核心的業務,但不是不計代價。作為管理團隊,並在董事會的治理之下,我們有責任審慎思考我們所擁有資產的價值,以及透過出售或持續經營,哪一種方式能創造更高價值。我先說到這裡。
- Chairman & CEO
- Chairman & CEO
I think the answer, Paul, did a great job. Amazing only two months here, a great job answering that question.
我覺得Paul的回答非常好。才來兩個月就能做到這樣,回答得很出色。
The only thing I'd maybe add to it is that, as I said at the first call I was on that we value what's core, what's non-core. That is still the case. Core assets for us are the dermatology, the GI, the eyecare, and the consumer side. But we did receive a number of inbound requests to acquire some of our product assets with very significant numbers that we have to evaluate. As such, we owe it to all of our shareholders, our debt-holders, to evaluate any inbound requests to acquire assets.
我可能唯一要補充的是,正如我在我參與的第一場電話會議上所說,我們會評估哪些是核心、哪些是非核心。目前仍是如此。對我們而言,核心資產是皮膚科、腸胃科(GI)、眼科護理,以及消費者業務。但我們確實收到多項主動洽詢,希望收購我們部分產品資產,且出價數字非常可觀,我們必須加以評估。因此,對所有股東與債權人而言,我們有責任評估任何主動提出的資產收購要約。
I think it's a positive statement of the Company that we have great assets that people are very interested in owning. So for that reason, there's -- those inbound questions are ones we're going to have to evaluate and do it to the best for our shareholders and our debt-holders and all of our stakeholders in the Company. That's what we are doing.
我認為這對公司而言是正面的訊號,代表我們擁有很好的資產,且有很多人非常有興趣持有。因此,對於這些主動詢問,我們必須進行評估,並以最符合股東、債權人以及公司所有利害關係人利益的方式來處理。這正是我們正在做的事。
On the second part of your question of Rochester, maybe just go a little bit more specifics on Rochester. As I mentioned, we did receive an FDA warning letter. We received it just on Friday, November 4; it was related to an inspection that was in February 2016 and then a follow-up of September of 2016. As I mentioned, we take these matters very seriously and work with FDA to respond to the warning letter and resolve as soon as possible.
至於你問題的第二部分——Rochester,我再更具體說明一些。如我提到的,我們確實收到FDA的警告信。我們是在11月4日星期五才收到;該警告信與2016年2月的一次稽查,以及2016年9月的後續稽查有關。如我所說,我們非常重視這些事項,並會與FDA合作回覆警告信,盡快解決。
I want to make clear, though, it does not impact the production or sales of any of our Bausch + Lomb products or anything at the site. It is specific to some medical devices that are -- the registrations are there at the site, and as such they were specific to those medical devices. But it does not relate to the manufacturing of the contact lens and other products at the Bausch + Lomb site in Rochester, New York.
不過我想澄清的是,這不會影響我們任何 Bausch + Lomb 產品的生產或銷售,或該據點的任何作業。這是針對某些醫療器材——其註冊是在該據點,因此是專門針對那些醫療器材。但這與位於紐約州羅徹斯特的 Bausch + Lomb 據點之隱形眼鏡及其他產品的製造無關。
Operator
Operator
Douglas Tsao, Barclays.
Douglas Tsao,Barclays。
- Analyst
- Analyst
Joe, you referenced a 4Q event in terms of finding a primary care solution for the GI business, and I think it was specific to Xifaxan. I was just wondering if you could help us understand a little bit about what you're thinking and some broad stroke description of what that solution might be?
Joe,你提到第 4 季會有一個事件,關於為 GI 業務找到一個基層醫療(primary care)解決方案,我認為是特別針對 Xifaxan。我只是想請問,你能否協助我們更了解你在想什麼,以及用比較概括的方式描述一下那個解決方案可能會是什麼?
- Chairman & CEO
- Chairman & CEO
Sure. Thanks for the question. So, as I've said on the call, we have a number of solutions for primary care. We actually have three different alternatives. We may do one or two of those alternatives. I will say, though, that's something that we're working very actively to work and go forward with.
當然。謝謝你的問題。所以,正如我在電話會議上說的,我們對基層醫療有多種解決方案。我們其實有三種不同的替代方案。我們可能會採用其中一種或兩種替代方案。不過我要說的是,這是我們正在非常積極推進、並將往前落實的事項。
On this primary care issue, I remind you, the issue we face is that Xifaxan is a great product. As we moved into the IBSD category, we realized that we needed to have some additional capabilities in the area of GP, FP, IM, general practice, family practice, internal medicine or primary care for the treatment of IBSD. Today we can only cover about 10% of that opportunity. We put forward a solution that we believe will allow us to cover 70% of the primary care opportunity with the programs that we have in mind.
就這個基層醫療議題,我提醒各位,我們面臨的問題是 Xifaxan 是一個很棒的產品。當我們進入 IBSD 類別時,我們意識到在 GP、FP、IM,也就是一般科、家醫科、內科或基層醫療領域,針對 IBSD 的治療,我們需要具備一些額外能力。目前我們只能涵蓋大約 10% 的機會。我們提出了一個解決方案,我們相信可讓我們透過心中規劃的方案,涵蓋 70% 的基層醫療機會。
So there's an opportunity for us to partner with another player. There's also an opportunity for us to build our own primary care capability. We're looking at both of those alternatives, along with one other alternative, and look to have that answer, as I said, in the fourth quarter we will get it done. That's the -- or the best I can answer at this point, given some of the questions that I also mentioned about the potential interest in the acquisition of that business unit.
因此,我們有機會與另一個業者合作。我們也有機會建立自有的基層醫療能力。我們正在評估這兩種替代方案,以及另一個替代方案,並希望如我所說,在第四季把答案定案、把事情做成。就目前而言,在我也提到的、關於可能有人對收購該事業單位的興趣等問題之下,這大概是我此刻能給的最佳回答。
Operator
Operator
Umer Raffat, Evercore.
Umer Raffat,Evercore。
- Analyst
- Analyst
I think the new disclosure on this call versus the press release is obviously on the 2017. If you allow me to, I just want to drill down 2017 in some detail here, perhaps on a bridge level, if possible.
我認為這通電話相較於新聞稿的新揭露,顯然是在 2017 年的部分。如果你允許的話,我想在這裡更深入地拆解 2017 年,若可以的話,或許用一個橋接(bridge)的層次來看。
Paul, you mentioned EBITDA will be down because of products facing generics. These products basically add up to about something like $800 million. They have expiries at various times. Let's say that $800 million gets cut into half, and it drops entirely to EBITDA. So that's a $400 million headwind.
Paul,你提到 EBITDA 會下滑,因為有產品面臨學名藥競爭。這些產品加總起來大概約 8 億美元。它們在不同時間點到期。假設這 8 億美元被砍半,而且完全反映到 EBITDA。那就是 4 億美元的逆風。
My question is -- there's a few offsets here as well. Number one, Salix, so you're doing about $70 million to $80 million better sales in Salix in Q3 versus you did in Q1 and Q2. You have some pricing tailwinds, about at least $100 million in additional price. You have some re-launches of [Ophthal] products, which is what you guys talked about last quarter. Then obviously SG&A cuts, because Q1 and Q2 were heavier this year than what Q3 is tracking, so SG&A cuts are an additional about $150 million, $160 million.
我的問題是——這裡也有一些抵銷因素。第一,Salix,所以你們在第三季的 Salix 銷售比第一季和第二季好大約 7,000 萬到 8,000 萬美元。你們有一些定價順風,至少約 1 億美元的額外價格貢獻。你們有一些 [Ophthal] 產品的重新上市,這是你們上季談到的。然後很明顯還有 SG&A 的削減,因為今年第一季和第二季比第三季目前的趨勢更重,所以 SG&A 的削減另外大約有 1.5 億到 1.6 億美元。
I put it together, it's a $400 million drop on headwind from products versus tailwinds of about $150 million in additional Salix sales, about $100 million on price, and at least $150 million on additional SG&A cuts. That right there kind of offsets each other. So I just want to understand, what am I missing, just so we understand 2017 much better?
我把它加總起來,產品帶來的逆風是 EBITDA 下滑 4 億美元;順風則大約是 Salix 額外銷售 1.5 億美元、價格 1 億美元,以及額外 SG&A 削減至少 1.5 億美元。這樣看起來彼此大致互相抵銷。所以我只是想了解,我漏掉了什麼,好讓我們能更好地理解 2017 年?
- Chairman & CEO
- Chairman & CEO
Let me -- I'll start and then I'll turn it to Paul. I think what we're trying to do here is take a look at all the moving pieces and put forth -- we're not trying to give 2017 guidance at this time. I think Paul was just trying to make you aware that there's some US exclusivity risk in 2017 and wanted to be transparent with that. I think Paul did a good job of trying to be transparent there. That is a potential exclusivity -- or loss of exclusivity.
我先——我先回答,然後再交給 Paul。我想我們在這裡要做的是把所有變動因素都看一遍,並提出——我們目前並不是要提供 2017 年的指引。我想 Paul 只是想讓你知道,2017 年在美國有一些獨占性(exclusivity)風險,並希望在這點上保持透明。我認為 Paul 在透明揭露方面做得很好。那是一個潛在的獨占性——或者說獨占性喪失(loss of exclusivity)。
But clearly, remember we do think that there is growth prospects in our Business. That's what Paul mentioned in terms of -- I think he said mid-single-digit growth in our core businesses and also higher on the EBITDA growth. But I think probably that's the best way I can answer it.
但請清楚記得,我們確實認為我們的業務仍有成長前景。這就是 Paul 提到的——我想他說的是核心業務中段個位數成長,以及 EBITDA 成長更高。但我想這大概是我能給的最佳回答方式。
- CFO
- CFO
Right. I'll jump on, too. Think about that core business that we talk about, mid-single digits, high-single digits in EBITDA growth in 2017 v 2016. I'm trying to isolate for you the growth drag. You did what I would hope, which is you start to look at the individual assets, you aggregate them, and you decide what is an appropriate degradation curve. You can take into consideration what you believe the right timing is, et cetera.
對。我也補充一下。想想我們所談的核心業務:2017 年相較 2016 年,營收中段個位數成長,EBITDA 高個位數成長。我試著幫你把成長的拖累因素單獨拆出來。你做了我所期待的事,也就是開始看各個單一資產,把它們加總,並判斷什麼是合適的下滑曲線。你也可以把你認為正確的時點等因素納入考量,等等。
I just wanted to point out that our revenue and EBITDA expectations for 2017 v 2016 are that revenue and EBITDA will be less. It will be less primarily because of the performance of those generic -- excuse me, those neurology assets, which will either have exclusivity, lose exclusivity during 2016 or in early 2017, as well as a drop-off in the generics business.
我只是想指出,我們對 2017 年相較 2016 年的營收與 EBITDA 預期是:營收與 EBITDA 會更低。之所以會更低,主要是因為那些學名藥——抱歉,是那些神經科資產的表現;它們將在 2016 年期間或 2017 年初仍具獨占性或失去獨占性,另外還有學名藥業務的下滑。
So all the other things that you ticked off are kind of captured in the all other, like what the remainder part are core assets, so we expect to grow mid-single digits and high-single digits at the EBITDA line. So I think that was a pretty clear set of hand signals. As what Joe said, we're not providing detailed 2017 guidance at this time, but we, as a team, felt compelled to provide those hand signals. I'll stop there.
所以你剛才列舉的其他項目,大致都包含在「其他」裡;也就是剩餘部分屬於核心資產,因此我們預期在營收端中段個位數成長、在 EBITDA 端高個位數成長。所以我認為那是一組相當清楚的訊號。如 Joe 所說,我們目前不提供 2017 年的詳細指引,但我們團隊覺得有必要提供這些訊號。我就說到這裡。
Operator
Operator
Chris Schott, JPMorgan.
Chris Schott,JPMorgan。
- Analyst
- Analyst
Just two questions here: One, coming back to the longer-term outlook for the Company, we're obviously seeing 2016 coming down, you're targeting 2017 revenue and EBITDA declining again next year. What does the longer-term growth of this Business look like? I guess you laid out some 2016 through 2018 trends with 2Q. Do those type of trends still hold after today's commentary, or just any color you can give us as we look past this eroding business would be helpful.
這裡兩個問題:第一,回到公司較長期的展望,我們顯然看到 2016 年在下修,你們也鎖定 2017 年營收與 EBITDA 明年再度下滑。這項業務的長期成長會是什麼樣子?我想你們在第二季時提出了 2016 到 2018 年的一些趨勢。在今天的評論之後,那類趨勢是否仍然成立?或者你們能否提供一些補充說明,讓我們在展望這個逐步侵蝕的業務之後的情況時有所幫助。
The second is on the ongoing erosion, again, in top-line EBITDA. Does that put more pressure on the Company to divest assets just to address some of the debt levels? Or are those processes kind of independent of each other? Thank you very much.
第二點是關於營收端 EBITDA 持續被侵蝕的問題。這是否會讓公司為了處理部分債務水位而承受更大的出售資產壓力?還是這些流程彼此算是相互獨立?非常感謝。
- Chairman & CEO
- Chairman & CEO
Maybe I'll start, and, Paul, feel free to add. Because some of the things that you're asking, Chris, go back to some of the things we talked about in our Q2 results. What we said and continue to believe is that if you look at our core Bausch + Lomb, the branded Rx business, we see that business as a good growing business. As Paul said, a mid- to single-digit growth rate of that business; the EBITDA will have an even higher single-digit growth. So think of it that way.
也許我先開始,Paul,你也可以隨時補充。因為你問的一些事情,Chris,會回到我們在第二季業績中談到的一些內容。我們當時說、而且現在仍然相信的是,如果你看我們的核心業務 Bausch + Lomb、品牌處方藥(Rx)業務,我們認為那是一個良好且成長中的業務。如 Paul 所說,該業務的成長率為中個位數到低個位數;而 EBITDA 會有更高的個位數成長。所以可以這樣理解。
But there are some things in our diversified business, in the neuro business that are one-time events, as you lose exclusivity. We're trying to be transparent on that loss of exclusivity. Obviously, we're going to do everything we can do to minimize that loss, but we're trying to be transparent to say that there is some challenges to that in the near term.
但在我們的多元化業務中、在神經(neuro)業務裡,有一些一次性事件,因為你會失去獨家權。我們正努力就這個獨家權到期的影響保持透明。顯然,我們會盡一切所能把這個損失降到最低,但我們也希望透明地說明,短期內確實會面臨一些挑戰。
But I want to be very clear, there are other programs and activities that we're going to look at there to help grow that diversified business with some additional promotional efforts on. We have some exciting products. We have a product, Migranal, that's been in that business as a smaller product, but it's got opportunities for growth. We're going to look at that.
但我想非常清楚地說,我們也會檢視其他計畫與活動,透過一些額外的推廣投入來協助多元化業務成長。我們有一些令人振奮的產品。我們有一個產品 Migranal,在該業務中原本是較小的產品,但它有成長機會。我們會去評估。
There are things we are doing with Wellbutrin, other things that we will do to continue to look for growth. Right now, we want to mostly reflect the fact that the loss of exclusivity that we expect over the next 12 to 18 months is something that we wanted to be transparent with.
我們也在 Wellbutrin 上做一些事情,還有其他我們將採取的措施,以持續尋求成長。目前我們主要想反映的是,我們預期未來 12 到 18 個月的獨家權到期影響,是我們希望對外保持透明的事項。
- CFO
- CFO
Yes. I'll take the liquidity question, Chris. Go back to my answer to David earlier, we do not need to sell assets to be okay from a liquidity perspective. That said, we -- on our Q2 call, we talked about our program to evaluate the potential divestiture of non-core assets to the extent that we can do that and we can improve our -- both our liquidity and our leverage situation. We will certainly pursue that if it makes sense. But we don't need to do that to be okay from a liquidity perspective.
是的。Chris,我來回答流動性問題。回到我先前對 David 的回答,從流動性角度來看,我們不需要出售資產也能維持良好狀況。不過,我們在第二季電話會議中談到,我們有一個計畫要評估出售非核心資產的可能性,只要我們能做到,並且能改善我們的——流動性與槓桿狀況。如果有意義,我們當然會推進。但從流動性角度來看,我們不需要這麼做才能維持良好狀況。
Operator
Operator
Gary Nachman, BMO Capital Markets.
Gary Nachman,BMO Capital Markets。
- Analyst
- Analyst
On your pricing strategy, what's the process behind the committee deciding which products to take price increases on and the magnitude of those price increases? The eight or so you took in mid-October, how much of that did you actually realize? So how important is pricing for you as a lever of growth going forward?
關於你們的定價策略,委員會決定哪些產品要調漲價格,以及調漲幅度的流程是什麼?你們在 10 月中旬調漲的大約八個產品,實際上你們實現了多少?因此,未來定價作為成長槓桿對你們有多重要?
- Chairman & CEO
- Chairman & CEO
Sure. I'll take that one. Maybe just a couple of -- go back on the facts and we did take some price increase in October, as you actually said. The overall price increase for us for an annualized basis was approximately 2%, so below the 2.3% consumer price index.
好的。我來回答。先回到幾個事實:我們確實在 10 月做了一些調價,正如你所說。以年化基礎計算,我們整體的價格調漲約為 2%,低於 2.3% 的消費者物價指數(CPI)。
I would say that, in terms of importance, we just obviously are looking at, the range was anywhere from 2% to 9%. What we have said based on the activities of our patient access and pricing committee, we came forward with a couple concepts. We would do single-digit price increases, number one. We would stay below the five-year weighted average of brand pharma pricing. So those are two principles that we are operating under.
我會說,就重要性而言,我們顯然是在觀察;調漲區間大約在 2% 到 9%。根據我們的病患可近性與定價委員會(patient access and pricing committee)的活動,我們提出了幾個概念。第一,我們會做個位數的價格調漲。第二,我們會維持在品牌藥定價五年加權平均之下。所以這是我們運作所依循的兩項原則。
I think as long as we continue to operate in that fashion, we think it's about the right thing to do in the pricing environment. Relative to individual decision on product A or product B, we're always just going to look at the relative factors in the marketplace like competition to make our decisions on any individual pricing.
我認為只要我們持續以這種方式運作,在目前的定價環境下,我們覺得這是比較正確的做法。至於個別產品 A 或產品 B 的決策,我們一向會看市場上的相對因素,例如競爭情況,來決定任何單一產品的定價。
But to be clear, that pricing is only going to be one element of our future. A large part of our future and what I think is currently not recognized in our Company is that we have a pipeline. We have pipeline products like brodalumab. We have the Visalta product. We've launched oral Relistor.
但要說清楚,定價只會是我們未來的一個要素。我們未來很大的一部分、也是我認為目前市場尚未充分認知的,是我們有研發管線。我們有像 brodalumab 這樣的管線產品。我們有 Visalta 產品。我們已經上市了口服 Relistor。
We have got a real exciting product that's a topical psoriasis product that we expect to file in 2017. It's a new product, so I think it will be much more important to driving the success of the Business.
我們還有一個非常令人振奮的產品,是外用乾癬產品,我們預期在 2017 年提交申請。這是一個新產品,所以我認為它對推動業務成功的重要性會更高。
Then relative to the question on pricing as to what percent is realized, usually it's in the -- we realized somewhere in the, let's call it, 60%, 65% or two-thirds of any price increase is approximately what one realizes after rebates and discounts.
另外,關於定價調漲實現了多少百分比的問題,通常我們實現的比例大概在——我們大約能實現 60%、65%,或約三分之二;也就是在扣除回扣與折扣後,任何調價大約能實現的比例。
Operator
Operator
Annabel Samimy, Stifel.
Annabel Samimy,Stifel。
- Analyst
- Analyst
So with the last decrease in guidance, it was pretty clear that you identified some key challenges. It was negative ASPs, it was GI business; it seemed like you made some good improvement on those challenges. So, now you have these new challenges in international and sustainable revenue trajectories, generic challenges.
所以在上一次下調財測指引時,你們很清楚地指出了一些關鍵挑戰。包括 ASP 下滑、GI 業務;看起來你們在這些挑戰上有做出不錯的改善。但現在你們又面臨新的挑戰:國際市場與可持續的營收軌跡、學名藥的挑戰。
And based on these new challenges that you've identified, I'm not really hearing clearly what the distinct strategies are to address them, other than reducing costs and investing in R&D. So I'm hearing more band-aid solutions. Am I missing something? Is there something distinct that you're doing that's going to offset some of these challenges that you're facing right now?
而基於你們所辨識的這些新挑戰,我沒有很清楚地聽到有哪些明確策略來因應,除了降低成本與投資研發之外。所以我聽到的更像是貼 OK 繃式的解法。是我漏掉了什麼嗎?你們是否有什麼明確且不同的作法,能夠抵銷你們目前面臨的一些挑戰?
- Chairman & CEO
- Chairman & CEO
So let me start and then I'll let Paul also contribute because he's been very active on many of these challenges. I'm going to refer you to slide number 20, though, in terms of things that we're doing to improve on the overall business performance.
我先回答,然後也讓 Paul 補充,因為他在許多這些挑戰上都非常積極。不過我會請你參考第 20 張投影片,裡面列出我們為改善整體業務表現所做的事情。
Clearly, the first and foremost, it starts with bringing the right people on the team. I have made some changes in the team. As I brought new people in, for example, Tom Appio took over the international business. Tom is going to do a great job for us, but he went in and took a look at where we were, what the assumptions are with his international business and wanted to make sure that he was transparent to us in terms of what the -- as we went through our quarterly business review. So building the new team and getting new people in place, I think, first and foremost. Of course, obviously, I've already mentioned Paul and how he looks at the projections, et cetera, is an important part of the team.
很明顯,第一且最重要的是,從把對的人帶進團隊開始。我已經對團隊做了一些調整。例如我引進新的人才後,Tom Appio 接手了國際業務。Tom 會為我們做得很好,但他上任後檢視了我們目前的狀況、他對國際業務的假設,並希望在我們進行季度業務檢討時,能就相關內容對我們保持透明。因此,建立新團隊、讓新的人到位,我認為是首要之務。當然,我也已經提到 Paul,以及他如何看待預測等,這也是團隊的重要一環。
The second thing I'd say is, I'm making investments in research and development. I'm making investments in quality. Bringing on Louis Yu to help me on the quality side was clearly a necessary item for us, not -- I brought him on, I knew I needed it, but I think it was evidenced by some of the challenges I've talked about in the call. That I need to get some incremental quality resources to help us to go forward with the future. That's part of what I think Louis will bring to the table. I'm already seeing great results from Louis in how he's looking at the quality aspects of our Business and what we're doing.
第二點我要說的是,我正在投資研發。我正在投資品質。聘請 Louis Yu 來協助我在品質面向的工作,對我們而言顯然是必要的——我聘他時就知道需要,但我想這也從我在這通電話會議中談到的一些挑戰得到了印證。我需要增加一些品質方面的資源,來協助我們面向未來。我認為這也是 Louis 能帶來的價值之一。我已經看到 Louis 在檢視我們業務的品質面向以及我們所做的事情上,帶來很好的成果。
We are investing in research and development. We could have made a decision, as Paul pointed out, to reduce R&D in the quarter, and/or the fourth quarter. We felt that the right thing to do is invest in research and development that we think are the opportunities for the future of our Company. So not to delay a filing of a novel product for psoriasis as an example.
我們正在投資於研發。正如 Paul 所指出的,我們本可以做出決定,在本季和/或第四季削減研發支出。我們認為正確的做法是投資於我們認為代表公司未來機會的研發。例如,不要延後一項用於乾癬的新型產品的申報。
But we do have to cut back, to your comment. We're going to reduce operating costs, go through a zero-based budgeting process. We expect that to save $75 million to $100 million in 2017, that initiative being led by Paul to help us to find that.
但如你所說,我們確實必須縮減一些。我們將降低營運成本,並推動零基預算流程。我們預期在 2017 年可節省 7,500 萬至 1 億美元,該項計畫由 Paul 主導,協助我們找出這些節省空間。
We're going to go after the places where we do supply chain rationalization on page 20. We think we got $150 million to $250 million. So these are some real specific action steps that we're going to take to address the issues that we've identified.
我們將著手處理第 20 頁所提到的供應鏈合理化領域。我們認為可帶來 1.5 億至 2.5 億美元的效益。因此,這些都是我們將採取的非常具體的行動步驟,用以解決我們已識別出的問題。
- CFO
- CFO
Yes. I want to chime in. As the new guy, I got a chance to look at two of the main engines that will drive us forward are the GI group and the derm group. I'd say that the GI groups, the changes that we made into that GI group going back before I joined, but things that were being implemented in, call it, the months before I joined, we are seeing a noticeable positive impact from the changes that were taken within that group. You're seeing that reflected in kind of the TRx trajectory.
是的。我也想補充一下。作為新加入的人,我有機會檢視兩個將推動我們前進的主要引擎:GI 團隊與皮膚科(derm)團隊。我會說,GI 團隊方面,我加入之前就已對該 GI 團隊做出的調整——也就是在我加入前幾個月正在落實的事項——我們已看到這些變革在該團隊內帶來明顯的正面影響。你也可以從 TRx 的走勢中看到這點。
I always love to say, it's like it gets hard when you look into factory sales because of all of those elements that I had mentioned about what can cause a quarter to look different than another quarter. But when it comes to TRx's and a trajectory of TRx's, that's the ultimate proof of the pudding for a branded pharma segment. I think we're seeing very good progress in the GI space.
我一直喜歡說,當你看工廠出貨(factory sales)時會變得很棘手,因為我提到的那些因素都可能導致某一季看起來與另一季不同。但就 TRx 以及 TRx 的趨勢而言,對於品牌藥業務來說,這才是最終的驗證。我認為我們在 GI 領域看到非常好的進展。
So what are we doing? We implemented, we are continuing to review and we're continuing to monitor the progress that GI team makes. I think they're doing a great job in moving in the right direction.
那我們在做什麼?我們已經實施相關措施,並持續檢視與監控 GI 團隊的進展。我認為他們在朝正確方向前進方面做得非常好。
So that doesn't sound like a band aid. What that sounds like is, we identified an issue. We deployed resources against it. We looked to see if it was effective. Then we hope to get the results and we're seeing the results in GI.
所以這聽起來不像是權宜之計。聽起來更像是:我們識別出一個問題。我們投入資源去處理它。我們檢視其是否有效。然後我們希望取得成果,而我們也正在 GI 看到成果。
Derm is a little bit different story and a little bit more complicated. There are certainly steps that we have taken and we will continue to take to improve the effectiveness of our derm group. You're seeing some positive results in the TRx progression very recently, so we are moving in the right direction.
皮膚科(derm)則是另一個故事,也更為複雜。我們確實已採取一些步驟,並將持續採取更多步驟,以提升皮膚科團隊的效能。你最近已在 TRx 的進展中看到一些正面結果,因此我們正朝正確方向前進。
A confounding factor is, I mentioned the shift in our model to one that includes our relationship with Walgreens, and dovetailing with that, a managed care strategy to ensure that our patients have access to our drugs, particularly in this case our derm drugs. As you put those programs in place, I dare say when you start, it's probably not the way you're going to finish because you need to iterate to what works both from the perspective of providing the opportunity for patients to have access to our products and enabling us to get an ASP that makes the activity of driving a demand Rx a productive exercise. We are not as far along in seeing the demonstrable results in the derm space.
一個干擾因素是:我提到我們的模式轉向包含與 Walgreens 的合作關係;同時配合一項受管制醫療(managed care)策略,以確保病患能取得我們的藥物,特別是在此情況下是我們的皮膚科藥物。當你把這些計畫建立起來時,我敢說一開始的做法很可能不會是最後的做法,因為你需要反覆迭代,找出既能讓病患有機會取得我們產品、又能讓我們取得一個使推動需求處方(demand Rx)成為有效投入的 ASP 的方式。在皮膚科領域,我們尚未走到能看到明確可證的成果那麼前面。
So to your point, I'd say this, the position we find ourselves, we need to be very efficient in how we deploy resources to any of the activities within our Company. We need to see results and we need to be patient with when these results will be achieved because some of these things don't happen in a quarter or a month or two months; they happen over time.
因此,回到你的觀點,我會這麼說:在我們目前所處的位置,我們必須非常有效率地將資源配置到公司內的各項活動。我們需要看到成果,同時也必須對成果達成的時間保持耐心,因為有些事情不會在一季、或一個月、兩個月內發生;它們需要時間累積。
I think you're seeing that we know how to do this by looking at the GI space. We're going to apply that same methodology to the derm space that we already have. But we're going to see the results as we go forward. That same thought process applies to each and every one of our business units. I'll stop there.
我認為你從 GI 領域可以看出我們知道如何做到這點。我們將把同樣的方法論套用到我們已經在進行的皮膚科領域。但我們會在往前推進的過程中看到成果。同樣的思維也適用於我們每一個業務單位。我就先說到這裡。
Operator
Operator
Andrew Finkelstein, Susquehanna.
Andrew Finkelstein,Susquehanna。
- Analyst
- Analyst
First, as a broader picture, with the new segments, last quarter you laid out a 2016 to 2018 vision for each of them. Could you just review what's changed, if anything, in the outlook for those? I know you're not giving 2018 guidance, but a lot of this is related to diversified products. But to what extent has your three-year outlook for the core segments changed?
首先,從更宏觀的角度來看,隨著新的事業部門,上季你為每個部門提出了 2016 到 2018 年的願景。你能否回顧一下,對於這些部門的展望是否有任何改變?我知道你不提供 2018 年的指引,但其中很多與多元化產品有關。那麼,你對核心部門的三年展望在多大程度上有所改變?
Then on specific products, could you talk a little bit about where you see Xifaxan revenue per Rx shaking out? Any initiatives on the hepatic encephalopathy side, because you've highlighted that as a major source of future growth? Then on oral Relistor, you highlighted formulary acceptance; any color you can give on the expectations for uptake and pricing relative to competitors? Thanks.
另外就特定產品而言,你能否談談你認為 Xifaxan 每張處方(per Rx)的營收會落在什麼水準?在肝性腦病變(hepatic encephalopathy)方面是否有任何措施?因為你已將其強調為未來成長的主要來源。再者,關於口服 Relistor,你提到已獲得處方集(formulary)接受;你能否補充一些對於採用速度(uptake)以及相對於競品的定價之預期?謝謝。
- Chairman & CEO
- Chairman & CEO
Sure. I'll start with the broader question on our commentary. Once again, we're not going to provide 2017 guidance, but what we tried to do last quarter is just give some overall indications of where we thought the Business -- what the growth rate trajectories would look like over a three-year time period. I think many of those things are still the things that I mentioned before in terms of just overall growth rate, top-line growth rate, and the thought -- the mid-single-digit rates and an approximately higher single-digit growth rate for the EBITDA level of generation. So I think those types of comments still stand.
好的。我先回答較宏觀的評論問題。再次強調,我們不會提供 2017 年指引,但我們上季嘗試做的是,提供一些整體性的指標,說明我們認為在三年期間內,業務——也就是成長率的軌跡——大致會是什麼樣子。我認為其中許多仍與我之前提到的一樣,包含整體成長率、營收(top-line)成長率,以及我們的想法——中個位數的成長率,並且在 EBITDA 產生層面約為較高個位數的成長率。因此,我認為這類評論仍然成立。
But the one thing that we are being -- tried to be transparent on is some of the questions and issues that we face relative to the neuro business or what we refer to as diversified business. Specifically relative to the loss of exclusivity that will occur in the 2017 time frame. I think that's all that we're trying to do is provide that with some transparency on that question.
但我們一直努力保持透明的一點是:我們在神經科業務,或我們所稱的多元化業務方面,所面臨的一些疑問與問題。特別是關於在 2017 年期間將發生的專屬權喪失(loss of exclusivity)。我想我們所做的只是針對這個問題提供更透明的說明。
On the other portion of your question, do we see opportunity with Xifaxan and hepatic encephalopathy? The answer is absolutely yes. If you think about the number of patients that are potential -- we think this is potentially a $5 billion opportunity just in hepatic encephalopathy if all patients were combined. Now, that's not going to happen, but we certainly think there is a much bigger opportunity than what we see today because of the importance of this product and what it means to reduce re-hospitalizations for the patients that have hepatic encephalopathy. So, important, our comment.
至於你問題的另一部分,我們是否在 Xifaxan 與肝性腦病變方面看到機會?答案絕對是肯定的。如果你想想潛在病患人數——我們認為僅在肝性腦病變領域,若涵蓋所有病患,這可能是一個 50 億美元的機會。當然,那不會完全發生,但我們確實認為,基於此產品的重要性,以及它在降低肝性腦病變病患再住院方面的意義,機會遠大於我們今天所看到的。所以,這是我們評論的重點。
On the Relistor, it's very early, as you know, but we did see some growth in the TRx's and the whole Relistor family as a result of launching the oral Relistor. I'm delighted to say that just over the last couple weeks, the actual number of Relistor prescribers in both the oral and subcutaneous has increased by 10% as we've gone out there with the new product labeling and the new product opportunity. So we're seeing an increase in the number of prescribers since the launch of just going back four or five weeks ago -- six, seven weeks ago. We're already seeing a 10% increase in prescribers.
關於 Relistor,如你所知,現在還非常早期,但我們確實看到因推出口服 Relistor 而帶動 TRx 以及整個 Relistor 產品家族的成長。我很高興地說,就在過去短短幾週內,隨著我們帶著新的產品標示與新的產品機會推向市場,口服與皮下兩種劑型的 Relistor 實際開立處方醫師數已增加 10%。因此,自推出以來(回溯四、五週前——六、七週前),我們看到開立處方醫師數量正在增加。我們已經看到處方醫師增加了 10%。
On managed care situation, we have 50% of commercial lives covered within just two months of the product launch. So we're making progress. We believe it's helpful for us for what we plan to do for the future success of this product.
在醫療保險給付(managed care)方面,產品上市僅兩個月,我們已覆蓋 50% 的商業保險人群。所以我們正在取得進展。我們相信,這對我們未來推動此產品成功的計畫會有所幫助。
Operator
Operator
Alan Ridgeway, Scotiabank.
Alan Ridgeway,豐業銀行(Scotiabank)。
- Analyst
- Analyst
Paul, maybe just for you, a lot of guys have asked about the liquidity and the debt. If we were to assume that there's going to be some refinancing involved with the debt as it comes due, now that you've been with the Company for a while, can you give us a sense for what your target leverage would be long term for Valeant? Where you'd like to work this down to over time?
Paul,可能先請教你,很多人都問到流動性與負債。如果我們假設債務到期時會涉及一些再融資,現在你在公司也待了一段時間了,你能否讓我們了解你對 Valeant 長期目標槓桿水準的看法?你希望隨時間把它降到什麼程度?
Then secondly, just on the commentary earlier about the higher rebating in the quarter on some of the branded products, is that due to timing of managed care coverage kicking in that you guys have negotiated this year? How should we think about rebating going into next year? I'll just leave it with that. Thanks a lot, guys.
第二個問題,關於先前提到本季部分品牌產品回扣(rebating)較高的評論,這是否是因為你們今年談妥的醫療保險給付覆蓋開始生效的時間點所致?我們應該如何看待明年回扣的走勢?我就先問到這裡。非常感謝,各位。
- CFO
- CFO
Al, I'll take the target leverage. Obviously, our goal is to dramatically reduce our leverage. We intend to do that through a number of ways. First, I'd point out that one of the advantages of our Company is that we enjoy a low tax rate. That low tax rate enables us to convert earnings to cash at a high rate.
Al,我來回答目標槓桿。顯然,我們的目標是大幅降低槓桿。我們打算透過多種方式來達成。首先我要指出,我們公司的優勢之一是享有較低的稅率。較低的稅率使我們能以很高的比例把獲利轉換為現金。
So we would expect, one, to be able to reduce debt through free cash flow. Two, we have talked a little bit already today about our potential for reducing the quantum of debt through sale of non-core assets. Three is, over time, yes, we will have some refi, but we would intend to grow our EBITDA, which definitionally reduces our leverage, and our target would be, over time, to get our leverage down below 4 times.
因此,我們預期:第一,可以透過自由現金流來降低負債。第二,我們今天也稍早談到,透過出售非核心資產來降低債務規模的潛力。第三,隨著時間推進,是的,我們會進行一些再融資,但我們也打算提升 EBITDA,按定義這會降低我們的槓桿;而我們的目標是,隨時間把槓桿降到 4 倍以下。
Now, that's a ways off. I get it. I understand, but that's our target. That's what we're working towards.
當然,這還需要一段時間。我明白。我理解,但那就是我們的目標。這就是我們努力的方向。
- Chairman & CEO
- Chairman & CEO
I'll take the question on the rebates. Yes, there are some higher rebates, but I think what we've done here is truly to look at -- Xifaxan is a good example. We've done two things, if you think about it, 2015 versus 2016. Number one, on 2015 coming into the year with the IBSD indication we wanted to get better access. In order to drive that better access, we did have to give incremental rebates.
我來回答回扣的問題。是的,確實有一些較高的回扣,但我認為我們在這裡所做的,是真正去檢視——Xifaxan 是個很好的例子。如果你把 2015 與 2016 做比較,我們做了兩件事。第一,2015 年在年初、伴隨 IBSD 適應症進來時,我們希望取得更好的可近性(access)。為了推動更好的可近性,我們確實必須提供額外的回扣。
Number two, we said that if we can remove some of the step therapy requirements with the higher rebates, we were willing to do that. Those are what's been driving some of the incremental rebates to make sure we get better access for our products for the patients and physicians to prescribe them. So that's really the primary thing, but I think we really talked about that in the previous call, it's being really -- some of the trends that we've seen in the previous calls.
第二,我們表示,如果透過較高回扣能移除某些階梯療法(step therapy)的要求,我們願意這麼做。這些因素推動了部分額外回扣,確保我們的產品能取得更好的可近性,讓病患與醫師能夠開立處方。所以這確實是主要原因;但我想我們在上一通電話會議已經談過,這其實——是我們在前幾次電話會議中看到的一些趨勢。
So let me close and say thank you, everyone, for your interest in our Company. We're going to be able to share with you more information over the next weeks ahead. If there's questions, I'd be glad to try to answer additional questions as well. We thank you, everyone, for participating in today's call. Have a great day, everyone.
最後我想做個結語並向各位致謝,感謝大家對我們公司的關注。在接下來的幾週,我們將能與各位分享更多資訊。如果還有問題,我也很樂意嘗試回答更多問題。感謝各位參與今天的電話會議。祝各位今天愉快。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call. You may now disconnect.
各位女士、先生,今天的電話會議到此結束。您現在可以掛線。